Sham-operated animals

taxonomy
descriptive



Compliance ; treatment

Heart failure ; uk
CHF
air pollution ; heart failure
voordelen ; cardiovascular system


HF
EH


diuretic ; heart failure


follow-up
Cell ; Anand
doxorubicin
blood transfusions
Heart failure ; bisphosphonates
cox proportional hazards
Caspase-3 gene expression ; heart failure
right heart failure ; pulmonary hypertension
Retrospective cohort

heart transplant recipients
inhospital mortality
Renal artery stenosis

HF ; pNA
molecular mechanism
tertiary referral centre
no production ; ec

Liver disease ; adults
dXA
FM
devices ; heart failure




heart failure ; Latin America
HF

Retrospective cohort
breathing ; heart beat

Heart rate


doctors
nutrition ; heart failure
Northwest United States

unilateral

heart failure
INTERvenTIONS

Heart failure

clin
Sci
trans


Internal reliability ; Cronbach
hypertension


cox regression analysis
implanted monitoring devices

patient safety
Ea ; afterload burden
periprocedural ; strokes
frailty ; heart failure
median age
heart failure
RAS ; atherosclerosis
microRNAs ; heart failure ; disease management
PSSS
management ; heart failure ; preserved ejection fraction
Cardiology ; bromodomain inhibition halts heart failure
AT
heart failure hospitalization ; cardiovascular death
cognitive function ; quality
co ; mixed linear models
vasopressin ; congestive heart failure
Mitral stenosis reversed ; medical treatment ; heart failure
cardiac transplantation
inpatient medical conditions
frailty ; HF

LV fibrosis ; ANS mice

dodson ; interest

CHF treatments
heart failure
intermediate frailty
Dynamic ; competitive collateral growth

autonomic balance
HFpEF
Jehovah ; Witness ; anemia
functional capacity
Heart failure ; cognitive impairment ; mortality
cardiology
follow-up
concurrent HF ; HF

hemostasis
extracorporeal
Heart failure ; disease
HF ; MI

remote ischemic conditioning ; patients ; heart failure
Heart rate variability ; risk stratification ; cardiac patients
cardiovascular disease
arrhythmia-related costs
systematic review ; network meta-analysis
pde2 ; HF
voordeel ; mortality ; sts HM
physician volume ; hospital volume
Medication regimen ; sST2
Heart failure ; public health
albumin level
median followup

Residual confounding
HF
Nights spent in hospital
mechanism ; ET ; CHF
eRK1/2 molecular scaffolds ; heart pathology
spironolactone ; systolic heart failure
cox proportional hazards models
Heart failure ;HF ; mortality
chronic heart failure ; bisoprolol
Functional MS ; degenerative MR

lVET ; aortic pressure curve
Cardiac symptoms ; children ; congenital lesions
Devices ; heart failure ;HF
Trastuzumab-related cardiotoxicity ; breast cancer
physician continuity
readmission metric
Tolvaptan ; vasopressin ; receptor
metric choice ; readmission metrics

propensity

black patients
MR ; MS
Cardiac amyloidosis
ejection fraction ; sex ; bNP
HFpEF
beta blockade
functional capacity
Robot-assisted training ; heart failure patients
functional capacity ; quality
Chronic HF

Pigs ; antiarrhythmic medication
Heart rate ; arterial pressure
hgb level ; HRQoL
preserved ejection fraction
mortality
cardiac ; inflammatory biomarkers
HF ; cardiovascular hospitalization
CHF patients ; intubated
Surgical tactics ; circulatory arrest
biomarkers ; chronic heart failure
heart failure ; emergency department
systolic dysfunction
American ; Canadian ; HF
North America
acute heart failure trials

therapy
AHA ; ESC
cPGs

MS
toxicity ; systemic blood pressure
patients ; heart failure
stand-alone diagnostic devices ;HF
end stage heart failure
HF


multiorgan failure ; sepsis
Nordic walking ; severe heart failure
psychometric testing ; Self-care ; Heart Failure index
heart failure
acute kidney injury
cox proportional hazards models
endothelial function ; dilatation
heart failure ; cox proportional hazard analyses
MS ; echocardiography
Pharmacological treatment ; acute heart failure

abnormal cardiac T2

heart failure
healthcare programmes
biomarkers
mAIN oUTCOME measURE



drug ; Japan

VO2max

Coronary angiography
dialysis patients ; device implantation
off-pump ; sternal sparing approach ; HeartMate II exchange
Hemodynamic phenotype ; failing Fontan
ESRD
Seattle Heart Failure model

HR ; HF
Heart failure ; preserved left ventricular ejection fraction
AI
acute heart failure
ingenuity pathway analysis
algorithms ; post- lVAD AI
nursing terminologies
race ; exercise training
voordelen ; anemia treatment ; patients ; heart disease

QRs

Rhythm- and rate-control strategies

public reporting ; quality ; patients
sinus rhythm ; AF
diagnosti performance ; filling pressures
care management ; telehealth ; medicare data

deficit index ; deficits
physicians ; HF
heart failure ; cardiac rehabilitation
Race ; spironolactone ; severe heart failure
Myocardial infarction ; Wistar rats

molecular level ; HF ; chromatin hyperacetylation
mortality
gLS ; CV events ; AF
MS

medication ; resting hemodynamics
mAIN oUTCOME
prognosis
systolic HF
postystolic function
lVAD implantation
Readmission to hospital ; heart failure
gross income ; expenditure ; health per capita

aac ; cardiac hypertrophy
patients ; heart failure
skeletal muscle abnormalities ; exercise capacity ; adults ; Fontan circulation
progressive disease ; hypertension ; kidney failure
chronic kidney disease ;CKd

anaerobic threshold ; heart failure
mitral regurgitation ; HF
CHF ; unilateral renal DNx ; cardiac autonomic
renin-angiotensin-aldosterone system inhibitors ; heart failure
abnormal HR variability ; sudden ; non-sudden cardiac death
inflammation ; metabolism ; heart disease
Heart block ; pulmonary artery snared ; BiVP
congenital heart lesions
functional MS
af patients ; echocardiographic examination
bioinformatic analysis ; microarray data ; heart failure
cardiovascular events
diuretic ; HF
CAD ; systolic HF
PVF ; recovery ; PB
patients
diabetes ; EO-cFUs
blacks ; VO2
odds ratios ; accounting ; hospital clustering
lVET ; follow-up measurement
nitroxyl ; hno ; acute treatment ; heart failure
physician continuity ; death ; urgent readmission ; discharge ; heart failure
hFrEF ; HFpEF

hospital-to-Home ; readmission reduction program ; congestive heart failure
net economic savings
HF
cRT ; dialysis-dependent patients
MS ;HF ; surgical indication ; MS

ICU mortality
Cardiac function ; pressure-volume conductance ; catheter system

beta-blockers
CHF patients
sst2 concentrations ; benefit ; BB therapy
idiopathic dilated cardiomyopathy
hypoalbuminemia ; heart failure
hypertensive LV dysfunction ; MR ; MS
prognosis ; c d HF
angiotensin receptor neprilysin inhibitor ; heart failure
Western blot analysis ; immunohistochemistry ; electron microscopy
diastolic dysfunction ; peripheral artery disease
unfolded protein response ; cardiac sodium current ; systolic human heart failure
ischemic cardiomyopathy ; male sex ; mortality
Exercise intolerance ; chronic heart failure
deficit index ; biological phenotype
Protective effects ; exercise training ;ET ; endothelial function
CV ; non-fatal stroke ; hospitalisation ; heart failure
AVd ; VVD ; co ; free wall RS
Fat ; cachexia ; right ventricle ; heart failure
Atrial fibrillation ;AF ; heart failure
ecCT ; advanced heart failure therapy
eligibility ; heart transplantation ; left ventricular assist device
coronary disease ; heart failure
dialysis patients
right ventricular function ; body composition ; heart failure
eCGs ; electrocardiographers
left ventricular assist device ; right ventricular support
incidence ; predictors ; ESRD ; outpatients ;HF
Wilcoxon
subclinical atherosclerosis ; linear models
resistin ; heart failure
fFM ; FM ; body weight ; CC
Renal artery stenosis ;RAS ; peripheral arterial disease
neurological ; cardiovascular
signalling pathways activating ; maladaptive cardiac remodelling
proteome ; HDL particles ; shotgun ;LC-MS
heart rate variation
social support ; barriers to exercise
rehospitalization
Cardiac cachexia ;cc
MS
proteins ;TAC
Mediterranean ; DASh diet scores
heart failure guidelines ; nurse leaders
frailty ; risk ; HF
Southeastern Minnesota residents ; HF
bundle branch block ; electrical activation sequence
hHF ; dPP-4 inhibitors ; drugs
AF ; clinical deterioration ; hFPEF
heart transplant ; ecCT
cRF
risk stratification ; death ; hospitalization ; heart failure clinic
Cardiac-resynchronization therapy ; heart failure
medications ; heart failure
miRNAs ; cardiac pathogenes
heart failure
bt ; DT
mortality
coronary heart disease ; stroke ; heart failure
MLHF Questionnaire
septal defects
iCD-HF patients
HF
hypotension

Î²-blocker ;bb ; sST2
discharge ; follow-up

extubated ; blood loss
techniek ; malfunctioning HeartMate II lVADs
Heart failure ;HF ; cardiovascular hospitalization
ST2 ; plasma samples
VEGF inhibition ; b ; cardiac function ; remodeling
biomarkers ; treatment ; HF
trastuzumab-related CHF
healthy ; aerobic
hospitals
Fatal ; nonfatal
transplants
patient safety
Peak VO2

pharmaceutically assisted
bromodomain proteins
economische

hypoalbuminemia ; lVAD
holosystolic murmur ; heart sound
psoriasis ; atherosclerosis ; incident cardiovascular events ; Rotterdam Study
Coronary artery disease ;CAD ; systolic heart failure ;HF
mortality ;HF hospital admissions ; transplant ; ventricular assist device
Heart failure ; rheumatoid arthritis ; tNF antagonist
haemodynamic ; neuronal stressors
lVAD implantation
renal dysfunction ; post-transplant morbidity
germline DNA ; genotyped
Heart failure disease management ; medical resource
Renal DNx ; circulating plasma NE ; CHF-INv rabbits

trastuzumab
NP assessment ; ED patients
Cardiac hypertrophy ; energy metabolism
HF
blood work drawn ; medication
soluble ; sp2 ; heart failure
Heart t2 ; heart failure ; arrhythmias
Caspase ; paced myocardium
frailty ; risk ; heart failure ; older adults
hHF ; saxagliptin ; sitagliptin
HF
acr ; CMS metrics
HDL-bound malondialdehyde ; HDL-induced ; ec
ED visits ; intubations ; congestive heart failure
derivation cohort ; CAD


Survival to hospital discharge

anemia ; adults ; heart disease
heart failure
regulatory subunit ;RI ; HF
heart failure ; reduced ejection fraction
cPET guiding exercise rehabilitation ; CHF
nfat ; mir-25 ; transcription factor ; hand2 in heart failure
Pediatric heart failure ;HF
eplerenone
renal denervation ; autonomic balance ; rabbits ; chronic heart failure
readmissions ; follow-up visits ; heart failure
resistin ; ejection fraction
Right atrial myxoma ; pulmonary embolism ; right heart failure
Orthotopic heart transplantation ; oHT ; heart failure
Myxomas ; right atrium ; pulmonary arterial vasculature
ecCT ; cardiac transplant recipients
deficit index
Diet score ; vegetables ; nuts ; whole grain intake ; mortality


iron
ED ; CHF
ventricular contractile reserve ; pulmonary hypertension
Gastrointestinal bleeding ; ventricular assist devices ; cardiac nurse
Soluble ST2 ; ambulatory patients ; heart failure
echocardiograms
Titin hypophosphorylation ; myocardial DD
remote monitoring ; hospital discharge ; patients with heart failure
bottleneck stent model ; chronic myocardial ischemia ; heart failure ; pigs
QT intervals ; SD
LV filling pressure ; severe systolic HF
medLine ; EMBAse ; cINAHL
benefit ; RAS- ; Î²-blocker uptitration ; HFpEF
cPCs ; functional capacity ; VO2
dysfunction ; pump failure ; driveline injury ; isolated pump replacement
ischemic ; inflammatory abdominal ; MT
EH ; HFpEF
Framingham Heart Study criteria ; HF ; EF
Nicorandil ; doxorubicin
therapies
aCP ; clinical practice guidelines
diuretics ; congestive symptoms ; heart failure ;HF
figuur ; chronic heart failure ; tachycardia
lVAS ; bridge to transplantation
Cardiac overexpression ; Mammalian enabled ; mena ; heart failure
east ; rhythm control therapy ; cardiovascular complications
HF
coronary artery disease ;CAD
noc outcomes ; outcome ; admission to discharge
HRQoL ; exercise training ; hgb
skeletal muscle mass correlated ; VO2
atrial fibrillation ; pacemaker
inpatient records ; patients discharged ; HF

cardiac resynchronization therapy ; dialysis-dependent patients ; heart failure
pneumonia ; surgical conditions
diastolic failure ; cardiomyopathic restriction to flow

pump exchanges ; pump malfunctions ; pump thrombosis ; hemolysis events
emergency cardiac catheterization
psychosocial factors ; exercise training ; heart failure ;HF
medical management ; heart failure ; children ; Canadian Cardiovascular Society guidelines
ees ; ventricular-arterial coupling ; SV
QRs
autonomic nervous system ; QTV
device implantation ; cRT capability
aRIC HF

responsiveheid to clinical change
degs ; osprey
therapy
electronic databases ; world health Organization ; HF ; LA
Medicare ; post-acute care transfer policy
cardiovascular reason
paediatric cardiac transplants
AF-free probability ; catheter ablation ; sinus rhythm
body mass index ; cRF ; treadmill exercise testing
human myocardial tissue ; pka subunits
iCD-HF patients
t1 mapping ; myocardial fibrosis

Medicare fee-for-service

white


ethics Rounds

therapeutic ; survival ; patients ; heart failure
ED visits ; CHF ; intubation rates
bisoprolol ; reducing mortality
Health Buddy Program ; content-driven telehealth system ; care management
muscle-wasting syndrome ; acquired heart failure ; Fontan
frailty ; elderly
ivabradine unloads ; left ventricle ; heart failure patients
RVPO ; BiVP ; co ; RS synchrony ; CS
anemia ; patients ; heart disease
cardiovascular death ; HF hospitalization ; exercise training
chronic heart failure ; lipoprotein functional properties
Heart rate ; aortic blood flow ; doxorubicin

Myocardial pde2 expression ; HF
resistin ; acute anthracycline-induced cardiotoxiciteit
acute autonomic nervous system modulation ; QTV ; HF patients
BAT ; sympathetic outflow ; parasympathetic activity
end-stage renal disease ; outpatients ; systolic heart failure
Neurohormonal abnormalities ; pathophysiology ; congestive heart failure ;CHf
echocardiographic ; reverse remodeling ; cardiac resynchronization therapy
parasympathetic neurotransmission ; acetylcholinesterase inhibition
renal DNx ; cardiac autonomic balance ; CHF ; sympathetic tone
Heart Failure ; Pathophysiology ; Medical Treatment Guidelines ; Nursing Management
biomarkers ; neurohormonal stimulation ; inflammation ; endothelial dysfunction

sympathetic activity ; i-miBG myocardial washout
right ventricle ;RV ; cardiac function
heart failure ;HF
HF
inhospital mortality ; bNP level ; mortality
cardiopulmonary exercise ; heart failure
RV dysfunction ; weight loss ; fat ;lean body mass ratio
chromatin subproteome ; mouse heart
HR reduction ; beta blockers ; exercise capacity ; hFrEF
inhibition ; protein kinase ; soluble guanylate cyclase ; contractile response
Student t test ; confidence intervals ;CIs
cPCs ; functional capacity ; heart failure ;HF
morbidity ; mortality ; HF
Mortality
PSSS ; social support ; btes
ctnt ; NT-probNP ; HF risk prediction
Jehovah's Witness ; sickle cell disease ; anemia
miRNAs ; therapeutic targets ; heart failure
physician continuity
l-type ca2+ currents ; Rad variant ; congestive heart failure
congestive heart failure ;CHf
Health Buddy Program ; ED
mRI scanner ; heart failure
cardiac stress ; antagonizing excessive Î²-AR drive
left pulmonary artery ; pulmonary artery
dobutamine ; furosemide dose ; oxygen flow
LVEF ; long-term mortality
Mediterranean ; DASh diet scores ; mortality ; women ; heart failure ; Womens Health Initiative
cPCs ; outcomes ; diabetes
resistin levels ; anthracycline-treated breast cancer patients ; cardiotoxicity
death ; transplantation ; circulatory assist device
Nursing-sensitive outcome change scores ; hospitalized older adults ; heart failure
therapeutic functions ; devices ; fluid overload
social support ; barriers ; exercise adherence
transcatheter ; surgery
Human resistin ; chemotherapy-induced heart failure ; humanized male mice ; breast cancer
insurance status ; comorbidities
black race ; mortality
chelation regimens ; remove heart iron
Timed Up & Go test ; advanced chronic organ failure
sterf ; worsening heart failure
ST2 level ;interquartile range
pressure ulcers ; surgical patients
HF ; valve plasty ; MS
PD ; refractory ; end-stage congestive heart failure ;CHf
NYHA functional assessment
beta blockers ; mortality ; heart failure
MT ; abdominal problems
follow-up
mortality
futility ; data monitoring board
complication
doppler echocardiography ; pulmonary hypertension
ejection fraction ; cardiac resynchronization therapy ; mild heart failure
septal wall CS ; AVd variation ; free wall CS ; VVD
echocardiography
circulating progenitor cells ; heart failure patients
etiologic causes ; acute RV failure ; left ventricular dysfunction
systolic ; diastolic mitral leaflet motions
myocardial diastolic dysfunction ;DD ; collagen deposition ; titin modification
ventricular ejection ; acute heart failure ; precapillary pulmonary hypertension
aortic valve insufficiency ; left ventricular assist device implantation
biventricular pacing ; left heart twist ; strain ; porcine model ; right heart failure
cardiac nurses

concordance c statistics ; UM/VA/VA-RT
absolute risk ; heart failure
cost-effective ; participatory
Czech Republic
cardiac catheterization ; thrombotic obstruction ; right coronary artery
Western blots ; monoclonal antibodies ; Ser83 phosphorylation ;HF
HFPEF ; sodium restriction ; ventricular ; vascular stiffness
echocardiographic ; invasive hemodynamic
chronic heart failure ;CHf ; sympathetic tone ; autonomic imbalance
California office of Statewide healthplanning and Development Patient Discharge
right atrium mass ; prolapse ; tricuspid valve
serum albumin ; survival ; left ventricular assist device implantation
functional capacity
nursing ; hospitalized older adults ; HF
CHF atrial explants ; c-Kit+ cells ; sham explants
Chinese herbal medicine ; adjunctive treatment ; dilated cardiomyopathy ; heart failure
implantable cardioverter-defibrillator deactivation

economic impact ; af ; heart failure ; QuÃ©bec ; Canada
cardiac Mena deletion ; cardiac dysfunction ; conduction abnormalities ; hypertrophy
mechanistic insight ; prolonged electromechanical delay ; dyssynchronous heart failure
trastuzumab ; cardiac comorbidities
bundle-branch block ;LBbb ; non-LBbb
Fontan failure ; systolic ventricular function ; liver disease
EH ; CH ; cardiac filling pressures
protein levels ; Western blot ; DNA fragmentation ; tunel ; autopsy samples
extracorporeal membrane oxygenation ; bridge to recovery ; infarction-related refractory right heart failure
pacing-induced dilated cardiomyopathy
Heart failure ; mortality ; Western society ; cardiovascular diseases
magnetically Levitated left ventricular Assist system ; Treating Advanced HF
anticoagulation ; therapy ; underlying heart disease ; rate control
inotropic effect ; beta blockers ; heart failure
PAD ; ankle-brachial index
HR reduction ; ivabradine ; TAC
NT-probNP ; circulation ; HF patients
energy metabolism ; heart failure ; hypertrophied heart
mortality ; morbidity ; cancers ; budget
mechanical cardiac support ; renal function
preserved systolic function ; therapeutic
patients ; ecmo group ; VAD ; ecmo+VAD groups
psoriasis patients ; smoked ; diastolic blood pressure ; body mass index
treatment group effects ; HRQoL
ED physicians ; suburban hospitals ; New Jersey ; New York
cox models ; ST2
functional MS ; LV dilatation ; functional MS
transfusion thresholds ; mortality
TM interventions ; sTS
HF
resource use ; quality of life
MADit-cRT ; device
neurological ; cardiovascular
BETs ; mouse TAC model ; human HF
chemical instability ; cogeneration ; nitrite ; vascular effects
patients ; aHF

HDL-induced NO production ; flow-mediated dilatation ; ET
dopamine ; nesiritide strategy
cutoff level ; NT-probNP
heart failure ; altered protein kinase
cox regression ; cardiovascular events ; psoriasis
cPG recommendations ; HF
Paco2 ; cerebral blood flow ; perfusion ; carotid bodies
Functional MS
HF epidemiology ; health service provision ; HF ; LA
heart failure ;HF
renal dysfunction ; mechanical cardiac
Heart failure ;HF ; debilitating chronic disease
ventricular assist devices ; device therapies
hemoglobin levels
exploratory factor analysis ; cfa
nontreatment
heart failure ; systolic heart failure
rhythm-control ; rate-control
CF lVAD patients ; AI ; heart failure
anemia ; patients with heart disease
ventricular dilatation
serum factors ; markers
device
p ; patients ; HF
iCD patients

HF cohort
computing readmissions ; hospital rankings
echocardiography ; shunt implantation
pro-adrenomedullin ;MR-proADm ; fFM
New York Heart Association ; quality-of-life scores
functional MS ; ring annuloplasty ; ischemic MR ; LV dilatation
Exercise intolerance ; heart failure
pathophysiology ;HF ; medical management
ventricular assist device ; extracorporeal membrane oxygenation ; renal function ; pediatric heart failure
interleukin receptor family member ; ST2 ; beta-blocker therapy ; chronic heart failure
bNP ; NT-probNP ; biomarkers ; heart failure
Cardiorespiratory fitness ; body mass index ; heart failure mortality ; Cooper Center Longitudinal Study
vasopressin receptor antagonist ; tolvaptan ; Japanese heart failure patients
diet ; exercise ; attention control
hospitals
acute HF
administratie ; trastuzumab-related CHF
long-term survival
cardiac death ; athletes
biomarker-guided clinical trial
hospital mortality
medical records
ejection fraction ;EF ; infarct size ; collateral growth ; myocardial perfusion
Heart failure ;HF ; sympathetic activity ; parasympathetic control ; heart
cardiovascular ; diabetes mellitus ; hypertension ; hyperlipidaemia
circulating fragments ; n-terminal pro-b-type natriuretic peptides ; plasma ; heart failure patients
heart failure ;HF ; left ventricular ejection fraction ;HFpEF
Atrial fibrillation ; congestive heart failure ; rhythm-control ; rate-control strategies
HF ; cardiac murmurs ; blood pressure
ATP demand ;XO-mediated ROS ; mitochondrial respiration ; contractile function
b treatment ; cardiac angiogenesis ; in vivo coronary perfusion ; cardiac fibrosis
autonomic modulation ; repolarization instability ; heart failure prone to ventricular tachycardia
tug test ; advanced COPd ; CHF ; cRF
pressure-overload-induced heart failure
Nursing ; social mandate
HF ; spontaneous VT ; beat-to-beat QT intervals
biventricular dysfunction ; isolated HeartMate II
hemodynamically unstable ; cPR
end-stage heart failure ; implantation ; long-term ventricular assist device
Pyridostigmine ; myocyte diameter ; collagen density ; left ventricle
isoproterenol ; cXL-1020 ; myocytes ; hearts
Exercise intolerance ; chronic HFPEF ;QOL
adenylyl cyclase ; g-protein coupling
systolic HF ; unclear etiology ; coronary angiography
mortality ; implantable cardiac defibrillator
jugular venous pressure ; peripheral oedema
Heart failure ;HF
clinical prediction rule ; CAD ; systolic HF
techniek ; redo sternotomy ; cardiopulmonary bypass
Surgical revascularization ; catheter-based revascularization
baseline hgb ; exercise training ; kccq
aggressive medical treatment ; HF ; HF symptom ; MS
MS ; HF ; functional MS ; medical treatment
sonographic ; histological ; functional abnormalities
parasympathetic function ; therapeutic ; slow HF
race ; outcomes ; exercise training ; ambulatory HF
mechanical cardiac support ; renal function ; end-stage heart failure
EH ; systolic blood pressure ; renal impairment ; hypertension
chronic myocardial ischemia ; heart failure
Morpholino-based knockdown ; nucleolin ; protein expression
rehospitalization
HFpEF
CAD ; severe CAD
diabetes mellitus ; cardiovascular disease
HF-related cachexia ; RV function ; body composition
diagnostic performance ; prediction rule
ecmo group ; egFR ; egFR
haemodynamic ; pulmonary
hospital ; cardiac specialty hospital ; rural South dakota
cognitive impairment ; mortality ; readmission
aCS procedures ; MT ; patients undergoing VAD
CVd ; psoriasis
energy substrate metabolism
SCHfi
Rotterdam ; psoriasis ; cardiovascular outcomes
HR ; tNF antagonists ; nbDMARD
Spironolactone ; hyperkalemia ; acute kidney injury
hereditary ; congenital abnormalities ; heart ; nontraumatic death
Fontan circulation ; skeletal muscle mass ; metabolic abnormalities

cardiovascular conditions ; HF
isolated HeartMate II lVAD
lVAD ; postoperative survival
mineralocorticoid receptor antagonists
right heart circulation ; right heart failure
MI ; HF
Fontan circulation ; sVR index ; cardiac index
isolated lVAD ; patients ; biventricular support
health insurance ; health system data partners ; u.s. Food and Drug Administration
cutoff value ; NT-probNP testing ; ED patients ; acute heart failure
blacks ; hypertension ; diabetes ; ischemic etiology ; socioeconomic status ; whites
bisphosphonate users ; heart failure
Cytoscape ; functional enrichment analysis ; DAVID
Raf-MEK1/2-ERk1/2 signalling ; remodelling
kosten ; survival
sustainability
maladaptive molecular processes
patient safety initiatives
HF-induced remodeling ; EMd prolongation
mouse HF model ; compensated LV hypertrophy ; HF ; hHD
heart failure ; preserved ejection fraction ; clinical doppler echocardiography
natriuretic peptide ; biomarkers
anticoagulants ; antiplatelet drugs ; heart failure ; atrial fibrillation
sympathetic ; parasympathetic activity ; HF
left ventricular longitudinal systolic strain ; cardiovascular events ; atrial fibrillation
heart transplantations ;LV assist device implantations ; heart failure admissions
functional mitral stenosis ; ring annuloplasty ; ischemic mitral regurgitation
Xanthine oxidase inhibition ; left ventricular systolic ; diastolic function ; cardiac volume overload
bNP levels ; patients ;PAD ; bNP measurements ; HF
patients ; heart failure ;HF ; Heart Failure Adherence ; retention trial ;HARt
HF ; preserved ejection fraction ;HFpEF ; hypertension
NYha functional class ; quality-of-life score
Myocardial infarction ; left anterior descending coronary artery occlusion
HFpEF
immunodetection ; NT-probNP ; antibodies
Nordic walking ; cardiac rehabilitation ; functional capacity ; heart failure
parasympathetic tone ; pyridostigmine ; ventricular dysfunction ; heart failure
Î²-Blockade ; cardiac angiogenesis ; heart failure ; VEGF signaling pathway
myocardial ischemic events ; cardiac resynchronization therapy
aortic valve surgery ; post- lVAD AI
unloading ; heart ; isolated HR reduction ; systolic heart failure
spironolactone ; systolic heart failure
Heart failure ; clinical burden ; adult medicine ; atheromatous coronary disease
Heart failure ;HF ; Latin America ;LA ; health service planning ; HF
rehospitalization ; medicare fee-for-service beneficiaries ; skilled nursing facilities
HF hospitalization ; cRT ;hazard ratio
palliative ; patients ; advanced disease
diagnostic test ; HFpEF
oxidative stress ; GTPase Rac1 ; hearts ; ANS mice
Resistin ; circulating mediator ; insulin resistance ; monocytes ; inflammatory stimuli
cardiovascular death ; urgent cardiac transplant
medications ; outpatients ; heart failure ; NCDR PINNACLE
nonselective ; selective beta-blockers ; cardiac sympathetic activity ; hemostasis ; heart failure
CHF patients ; emergency department ;ED ; intubated
mortality ;LCX ; LAD ; two-vessel disease model
RV dysfunction ; weight loss ; abnormal body composition ; HF
congestive heart failure
mitochondrial structure ; sarcomeric microstructure
heart failure ; Emergency Department ;ED ; ED volume
non-ischemic ; ischemic heart failure
pPR ; acr ; CMS
gut ; inflammation ; dietary interventions ; heart failure patients
heart failure ; reduced ejection fraction
Intravenous iron ; heart failure ; iron deficiency
robot-assisted gait therapy ; LokomatÂ® system ; heart failure patients
stress conditions ; maladaptive remodelling ; heart failure




psoriasis ; systemic/UV treatment
NT-probNP ; HF patient plasma ; immunoprecipitation ; mass spectrometric analysis
Chromatin-associated proteins ; chromatin structure ; DNA
diastolic dysfunction ; HFPEF
right ventricle overload ; stroke volume ; left ventricular ejection time ; lVET
Î²-Adrenergic receptor blockade ; hospitalizations ; heart failure ;HF
PD ; therapy ; severe end-stage HF
transoesophageal echocardiography ; patent ; thrombosis
mutant mice overexpressing hand2 ; healthy heart muscle cells ; pathological hypertrophy
physician follow-up ; discharge ; death ; readmission ; heart failure
dialysis patients ; echocardiographic
zSF1 rats ; heart failure ; preserved ejection fraction
consenting ambulatory HF patients ; left ventricular ejection fraction
QT variability ;QTV ; repolarization lability ; QTV ; risk predictor ; sudden cardiac death
Cross-talk between the heart ; adipose tissue ; cachectic heart failure patients ; body composition
arterial tonometry ; lVET carries ; precapillary PH ; heart failure
impact ; heart magnetic resonance imaging ; chelation choices ; heart disease ; thalassaemia
paraDIGm-HF ; paradigm shift ; chronic heart failure ; Chronic heart failure ; cardiology
aIM ; implantable cardioverter-defibrillator deactivation
conscious ; chronically instrumented New Zealand White rabbits ; renal DNx ; pacing-induced CHF
et ; HDL function ; ET ; CHF-NYha-IIIb ; HDL function
catheter ablation ; antiarrhythmic drugs ; rhythm control therapy
lVET ; sensitivity ; death
exertion ; therapeutic treatments ; abnormal exercise ; hemodynamic status
Cardiac failure ; diabetes ; molecular mechanism ; diabetes ; heart failure
pulmonary hypertension ;PH ; heart failure
Beta-blocker dose ; resting HR
CHF ; therapeutic interruption ; activated neurohormonal systems
uptitration ; heart rate ; renal function ; spironolactone
microRNAs ;miRNAs ; heart failure
mRI ; tidal respiration ; myocardial t1 ; swine ; heart failure
diagnosis ; early medical management ; HF
miRNAs ; cardiac remodeling ; heart failure
cutoff ; negative predictive value ; e-septal
cardiovascular disease ; dRS deciles
inappropriate therapy
AMI mortality rates
proteins ; strong acid
frailty ; risk ; heart failure ;HF
heart failure ; bisphosphonates
beta-blocker therapy
psoriasis ; cardiovascular disease ;CVd
pde2-overexpressing cardiomyocytes ; norepinephrine-induced hypertrophic
readmissions
cardiovascular disease
interne ; external validity ; kosten
POc technology
Rhythm control therapy
RAS-blocker uptitration ; clinical outcome ; hFrEF ; HFpEF
diastolic dysfunction ; filling pressures ; doppler echocardiography
Hemoglobin ; exercise training ; health status ; chronic heart failure ; HF-acTION
cardiac dysfunction ; subcellular alterations ; metoprolol ; heart failure ; myocardial infarction
Myocardial collagen ; collagen cross-linking ; titin isoforms ; phosphorylation
Cardiac magnetic resonance postcontrast ; heart failure ; preserved ejection fraction
systems proteomics ; cardiac chromatin ; nucleolin ; cellular plasticity ; cardiomyocytes
cardiotoxicity ; doxorubicin ; anti-neoplastic agent ; cancers
heart failure ; preserved left ventricular ;LV ; ejection fraction
symptomatic adult Fontan ;SAF
natriuretic peptides ; emergency ; ambulatory
AlphaLISa ; immunoassays ; NT-probNP
HF ; rheumatoid arthritis ;RA
hospital rates ; HF patients ; CMS
implantable cardioverter-defibrillator deactivation
sinus rhythm ; antiplatelet agents ; anticoagulants
c-statistics ; biological phenotype ; deficit index
Î²-Blocker-induced enhancement ; cardiac angiogenesis ; cardiac function ; remodeling
index admission
Bax ; bcl-2 proteins
GDMT ;control group ; GDMT ; BAT ;treatment group
heart failure ; CLcnka sNP
alendronate ; risk ; alendronate ; heart failure
transduction ; signalling proteins

Plasma samples ; HF patients
regulation ; feeding ; nutritional strategies ; anti-inflammatory effects ; CHF
diastolic dysfunction ; cause mortality
aCS ; oHT bridged to transplant ; MT ; VAD
RAS- ; Î²-blocker dose
drugs ;HF ; reduced ejection fraction ;HFrEF
Kansas City Cardiomyopathy Questionnaire ; heart failure ; preserved ; ejection fraction
heart failure ; preserved ejection fraction ; hFPEF
bNP ; NT-probNP ; coronary artery disease ;CAD
Functional mitral stenosis ;MS ; ring annuloplasty ; ischemic mitral regurgitation ;MR
heart failure-related hospitalization ; death ; left ventricular ejection fraction
refractory congestive heart failure ; peritoneal dialysis
heart failure ; elevated left atrial pressure
lean ; zSF1 group ; hypertensive ; obese ; zSF1 groups ; hypertensive ; diabetic
tissue ; doppler imaging ; left ventricular filling pressure ; systolic heart failure
Heart failure ; preserved ejection fraction ;HFpEF ; cardiovascular morbidity ; mortality
MT ; VAD groups ; aCS
diastolic dysfunction ; HFPEF
Mammalian enabled ; mena ; cytoskeletal actin dynamics ; heart failure ;HF
Gastrointestinal bleeding ; ventricular assist devices
ARNI inhibitors ;angiotensin-receptor neprilysin inhibitors
fes ; preserved ejection fraction ;HFpEF
Myxomas ; cardiac benign tumors ; left atrium
nicorandil ; cytotoxic effect ; doxorubicin ; ehrlich carcinoma
ambulatory iCD patients ; predictor ; mortality ; multivariable regression
Heart failure ; preserved ejection fraction ; hFPEF ; cardiovascular reserve
Renal denervation ;DNx ; CHF patients
physician follow-up ; discharge ; physician continuity ; heart failure
Crude rates ; severe hyperkalemia ; acute kidney injury ; spironolactone
activating myocardial pde2 ; intracellular antiadrenergic therapeutic strategy ; HF
carotid intima-media ; psoriasis
coronary occlusion ; collateral growth ; stent occlusion
HF hospitalization
exercise ; diet
voordelen ; spironolactone
rv dysfunction ; cardiac cachexia
eCG parameters ; effect ; cRT
Mechanical dyssynchrony ; QRs complex ; cRT
pharmacologic treatment ; pharmacologic
IE ; heart failure ;HF ; cRT-d recipients
chronic heart failure ; Hungary
breast cancer patients ; trastuzumb-related CHF
remote monitoring ;RM ; heart failure
Process redesign
circulating forms ; NT-probNP
PVf ; PB cycle ; low BP
transfusions ; heart disease
control group ; exercise group
sst2 ; low-dose BB ; cardiovascular event rate
ecCT
aerobic capacity ; left-hand grip ; body weight ; waist circumference ; anxiety
Myocardial loss ; iRS1 ; iRS2 ; heart failure ; p38alpha MAPK ; insulin resistance
heart failure ; hypertensive heart disease ; angiotensin II infusion ; nephrectomy ; salt loading
Shortened lVET ; ICU admission ; precapillary PH ; heart failure
Renal dysfunction ; all-cause mortality ; cardiovascular events
isoprenaline infusion ; SDQT ; hNorm ; HF
heart failure ; preserved ejection fraction ; myocardial infarction
coronary artery disease ; systolic heart failure ; unclear etiology
Ea ; total arterial compliance ;TAC ; end-systolic elastance ; ees
aldosterone antagonist ; heart failure
Genetic susceptibility ; anthracycline-related congestive heart failure ; haematopoietic cell transplantation
cardiovascular ; diabetes mellitus ; atrial fibrillation ; coronary artery disease ; HFpEF
Renal dysfunction ; long-term mortality ; myocardial infarction ; coronary artery bypass grafting ;CABG
Biventricular support ; HeartMate II lVAD ; CentriMag rVAD
angiogenesis ; post-myocardial infarction heart ; progression to heart failure
pde2 ; failing hearts ; desensitizes ; acute Î²-AR stimulation
surgery ; aggressive medical treatment ;HF ; hypertension ; vasodilators ; diuretics
eGFR ; diuretics ; uncontrolled hypertension ; ESRD
heart failure ; hospitalisation
Point-of-care systems ; NP levels ; ED ; community outpatient settings ; acute heart failure
EO-cFUs ; reduced mortality ;hazard ratio
trastuzumab ; CHF ; nontrastuzumab users
anemic ; iron-deficient adult patients ; heart disease
aggressive dose uptitration ; HR reduction ; beta-blocker therapy
acute heart failure ; aHF ; heart failure ;HF
psoriasis patients ; mild disease ; atherosclerosis ; cardiovascular events ; psoriasis
HF remodeling ; EMd ; dyssynchronous failing heart
Pyridostigmine ; vascular endothelial growth factor protein ; left ventricle ; myocardial angiogenesis
idiopathic dilated cardiomyopathy cohort
cardiac growth ; plasticity ; disease recapitulates ; chromatin remodeling
CHF ; international Classification of Diseases ; Ninth revision
medline ; EMBAse ; cochrane databases ; clinical trial registries
egFR ; VAD group ; ecmo+VAD group ; ecmo group
Ea ; TAC ; HR ; ees ; ivabradine-
ERC ; pure epicatechin
Robot-assisted gait therapy ; LokomatÂ® system ; heart failure patients
cRF ; HF mortality risk ; men ; HF risk factors
RV dysfunction ; lower body mass index ; fat mass index ; cachexia
HF ; HF
myocardium displays ; post-translational modification ; pka subunits ; downstream signaling
Care management ; content-driven telehealth technology ; health outcomes ; Medicare beneficiaries
HFPEF
cardiovascular disease ; heart failure
HDL function ; CHF ; ET ; HDL-mediated vascular effects
HF risk factors ; fit men ; HF mortality ; unfit men
physician adherence ; HF cPGs
lVAS
biomedical reasons ; nonprescribing
black race ; HF hospitalization ; cardiovascular mortality
dopamine ; nesiritide
nonprescribing ; chart review
Shunt implants ; transseptal catheterisation ; transoesophageal echocardiographic guidance ; anaesthesia
isoelectric focusing ; RIÎ± ; ser77 ; ser83 ; vivo phosphorylation sites
NT-probNP ; MR-proANp ; MR-proadm
tNF antagonists ; HF hospital admissions ; nbDMARDs ; RA
epidemiology ; myocardial infarction ;MI ; heart failure ;HF
Heart rate reduction ; exercise performance ; heart failure ; ejection fraction ; beta-blocker
HeartMate II insertion ; biventricular support ; HeartMate II implantation
ms ; Killip class
mADIt-cRT ; multicenter Automatic Defibrillator Implantation ; Cardiac resynchronization Therapy
natriuretic peptide ; bNP ; creatinine ; natremia
RAS ; hypertension ; nephropathy ; congestive heart failure
functional MS ; valve plasty ; degenerative MR ; LV
elastic N2 bus segment ; PEvk segment
management ; end stage heart failure Heart failure ; public health problem ; europa ; North America
Nicorandil ameliorates mitochondrial dysfunction ; doxorubicin-induced heart failure ; rats
HeartMate ; left ventricular assist system ; lVAS ; patients ; advanced heart failure
cXL-1020 converts ; hno ; inactive cXL-1051
arterial elastance ; ea ; pulsatile afterload ; heart ; pressure volume relation
pharmacologic ; acute HF ; adverse event rates ; chronic HF
quantitative proteomics ; chromatin-associated proteins ; detergent
heart failure ; mechanical support devices ; Cardiology-cardiovascular Surgery Consensus Report Heart failure
heart failure patients ; implantable cardioverter-defibrillator
Self-care of Heart Failure index ; schfi ; psychometric profile
therapy ; atrial fibrillation ; carvedilol ; metoprolol
SDQT ; SD ; RR intervals ;SDRR ; index ; QTV ; heart rate variability
devices ; gastrointestinal bleeding
readmission rate ; patients ; heart failure
Logistic regression models ; risk ; secondary outcome ; death
egFR ; VAD group ; ecmo+VAD group ; renal function
e/eseptal ; e/emean ; s'septal ; QRs width
Physician volume ; lower mortality ; HF ; noncardiologist physicians
LV ejection fraction
diuretics ; morbidity ; mortality
congestive heart failure
IVc occlusion ; CO correlated ; twist ; apical rotation ; RS ; RS synchrony ; CS
CHF ; ED visits ; CHF patients intubated
emergency department ; acute heart failure clinical trials
zebrafish ; nucleolin ; genomic reprogramming events
physician adherence ; class I recommendations
gLS ;HR ; ci
sst2/low-dose BB ; sst2/high-dose BB
cardiac events
ejection fraction
HF complicating AMI ; high mortality
exercise ; diet
odds ; risk-adjusted mortality
magnet(Â®
HF ; drug treatment ; PAF biosynthetic enzymes ; lyso-paf-AT
cardiac magnetic resonance imaging ; t1 mapping ; invasive hemodynamic assessments
HF ; preserved ejection fraction ; pEF ; uptitration ; hospitalization
mouse HF model ; hh ; salt loading ; uninephrectomy ; ANG II infusion
RAS ; neprilysin inhibition ; chronic heart failure ; systolic dysfunction treatment
tidal respiration ; gadolinium-chelate contrast agent
Medicare inpatient data ; HF admissions to acute care hospitals ; United States
idiopathic dilated cardiomyopathy ; tuscany
Morbidity ; mortality ; HFpEF ; patients ; HF ; reduced EF
DAPc ;dystrophin-associated protein complex ; sarcomeric microstructure
dopamine ; nesiritide ; acute heart failure ; renal dysfunction ; acute heart failure
catheter ablation ; atrial fibrillation ; heart failure ; preserved ejection fraction
eCG ; congenital accessory pathways ; ion channelopathies ; cardiomyopathy
heart failure ;HF ; risk stratification ; inpatient ; outpatient models
conscious HF rats ; pyridostigmine ; basal heart rate ; vagal ; sympathetic control ; heart rate
intravenous iron ; exercise tolerance ; heart failure
erythropoiesis-stimulating agents ; anemia ; heart disease
knockdown ; BET bromodomain-containing protein 4 ;brd4) ; cardiac tissues
in-trial resource utilization ; unit costs ; QuÃ©bec Health Insurance Board databases ; disease-specific costs ; Ontario Case Costing Initiative
mitral valve plasty ; degenerative mitral regurgitation
carvedilol ; metoprolol ; inappropriate therapy ; heart failure patients ; devices
HF ;heart failure ; t2d ; type 2 diabetes ; Skm ;skeletal muscle
public health ; air pollution ; industrial areas ; cardiovascular health
molecular biomarkers ; pathophysiology ; chronic HF
cardiopulmonary exercise ; quality of life score ; muscular strength ; quadriceps force
Myocardial titin hypophosphorylation ; heart failure ; ejection fraction ; rat metabolic risk
circulating NT-probNP concentration ; antibodies targeting nonglycosylated ; nonterminal epitopes
University of Connecticut Heart Failure Center ; cardiologist ; heart failure nurse practitioner
serum creatinine level ; serum potassium level
PD ; weight loss ; diuretic response ; peripheral edema ; functional
echocardiographic predictors ; response ; cardiac resynchronization therapy ; cRT
HeartMate II lVAD ; CentriMag rVAD
HF ; MI ; preserved ; reduced ejection fraction ;EF
anemia ; chronic heart failure ;HF
Hum- retn mice ; cardiac mRNA levels ; inflammatory ; cell adhesion genes ; Retn ; mice
chromatin subproteomes ; heart failure ; chromatin structure
HFpEF ; kccq
nbDMARD ; tNF antagonist
voordelen ; structured exercise programme ; heart failure
af ablation
wind failure ; pediatric mechanical cardiac support
Chronic heart failure ; transforming growth factor beta-dependent yield ; functional decline ; atrial explant-derived c-Kit+ cells
RV failure ; diagnosti procedures ; management strategies ; intrinsic left ventricular dysfunction
readmission ; follow-up visits
Mortality ; inpatient admissions ; hospital days ; emergency department ;ED
economic models ; Canadian ; mandatory ; systematic monitoring ; lVAD
echocardiographic score ; cRT response
heterogenous improvement ; ejection fraction
If-channel inhibition ; hemodynamic status ; exercise tolerance ; heart failure ; preserved ejection fraction
Cardiac insulin-resistance ; mitochondrial energy production ; systolic heart failure ; pressure-overload hypertrophy
CHF ; fat ; carbohydrates ; proteins ; water
pigs ; inferior vena cava ;IVc ; snared to decrease CO
doxorubicin ; ip ; serum resistin ; Hum-retn mice
kosten ; high-volume physicians
rheumatic ; MS
deactivation

HF rats ; pyridostigmine ; stroke volume ; ejection fraction ; cardiac output ; contractility ; left ventricle
total myosin binding protein-c phosphorylation ; Ser23/24 troponin I phosphorylation ; HF
aldosterone receptor antagonists ; morbidity ; mortality ; systolic heart failure
uPR effectors ; protein kinase ; r-like ER kinase ;perk ; calreticulin ; CHOp ; HF tissues
hFrEF ; exercise performance ; resting HR ; beta-blocker therapy
echocardiographic ; n-terminal pro-brain natriuretic peptide ; inflammatory markers
cox hazard models ; time to ESRD ; to death ; ESRD ; death ; predictors ; ESRD
randomised-controlled trials ;RCts ; observational cohort studies
heart failure ; heart failure nurses ; follow-up ; cardiology services
heart failure ;HF ; cardiopulmonary exercise test ; anaerobic threshold ;AT
renal dysfunction ; stroke ; myocardial infarction ; heart failure ; CABG
XO inhibition ; cardiomyocyte bioenergetics ; LV function ; chronic aCF ; rat
carvedilol ; thromboembolic events ; heart failure ; Î²2-receptor haplotype status
pyridostigmine ; methylatropine ; propranolol ; cardiac sympathovagal balance
paf ; metabolic enzymes ; heart failure
trastuzumab ; cardiotoxiciteit ; congestive heart failure ;CHf
Phosphodiesterase-2 ; failing hearts ; blunts beta-adrenergic responses ; cardiomyocytes
lipolysis ; energie expenditure ; natriuretic peptides ;NPs ; CC
cox proportional hazards models ; health behaviors ; health status
east ; rhythm control therapy ; AF ; cardiovascular complications ; AF
hearts ; mena ; cardiac injury ; mena ; HF pathophysiology
scn5a transcript ; uPR ; downregulation ; cardiac genes ; HF
gls ; index beat method ; CV ; cox proportional hazards analyses
VAD group ; ecmo+VAD group ; ecmo group
tAPse ; PASp ; nonsurvivors ; PASp ; tAPse
Right ventricular ;RV ; left ventricular assist device ; lVAD
albumin levels ; nutrition ; inflammation ; hepatic function ; lVAD implantation
ST2 ; reclassification ; risk ; c statistic ; net reclassification ; integrated discrimination
post-hCT CHF ; hCT ; City of Hope
non-ischemic ; ischemic heart failure ; biomarkers ; heart failure
CHF-developed infarcted animals ; left ventricle end-diastolic pressure
womens Health Initiative ; HF hospitalization
Peak oxygen consumption ; oxygen pulse
dialysis-dependent patients ; HF ; cRT implantation
rv ; pathophysiologic mechanisms ; RV dysfunction
middle-aged recreational athletes ; sudden cardiac deaths
Ambient air pollution ; cardiovascular health ; acute myocardial infarction
economic climate ; NHs ; behavioural-change ; chronic disease ; exercise programmes ; acute hospital facilities
CV deaths ; non-fatal stroke ; hospitalisations ; heart failure
biomarkers ; molecular dysfunction ; chronic HF
kccq ; kaplan-meier curves ; death ; hospitalization
cRT-d ; IE ; defibrillator-only therapy
HR dynamics ; non-linear ; HR variability ; risk stratification
diagnosti procedure ; alternatieve treatments
obesity ; diabetes mellitus ; metabolic risk factors ; comorbidities ; heart failure ; preserved ejection fraction
atrial fibrillation ; atrial tachyarrhythmias ; ATP ; shock therapy
hypoalbuminemia ; postoperative mortality ; left ventricular assist device ; lVAD
AMI ; heart failure ; kidney infection ; UTI
Cardiopulmonary exercise ; echocardiographic assessment ; myocardial function ; left ventricular filling
percutaneous coronary revascularization ; hemodynamically
speckle tracking echocardiography ;STE ; BiVP ; right ventricular pressure overload ;RVPO
pathophysiologic mechanism ; renal underperfusion ; renin- angiotensin-aldosterone pathway
Olmsted County ; Minnesota ; MI diagnosed ; HF
proteomics ; pathway analysis ; pressure-overload-induced heart failure ; mitochondrial-targeted peptides
neurohumoral blockers ; HF ; co-morbidity burden
odds ratio ;hazard ratio ; death ; HF concurrent ; AMI admission
sensitivity ; CAD ; severe CAD
inhibition ; vascular endothelial growth factor ;veGF ; compensatory hypertrophy ; cardiac failure
age-dependent effect ; left ventricular ejection fraction ; long-term mortality ; patients with heart failure ; Heart Failure Survey ; ISrael
HF
IC ; multicenter Automatic Defibrillator Implantation trial-Cardiac resynchronization Therapy
testosterone therapy ; exercise rehabilitation ; chronic heart failure ; low testosterone status
Health Buddy Program ; chronic obstructive pulmonary disease ; mortality ; congestive heart failure
RAS ; doppler ultrasonography ; computed tomographic angiography ; magnetic resonance angiography
nicorandil ; cardioprotection ; apoptotic signaling pathway ; DNA fragmentation ; mitochondrial ultrastructural
atrial fibrillation ;AF ; heart failure ;HF ; stroke ; anticoagulation
echocardiographic score ; LV reverse remodeling
perk inhibition ; scn5a ; Kv4.3 mRNA levels ; na+ channel mRNA splice variants
bottleneck stent ; myocardial infarction ; antiplatelet medication
sex ; EF ; bNP ; HF patients ; bNP ; sex ; EF
Trastuzumab ; CHF ; nontrastuzumab users ;hazard ratio ;HR
Rad variant ;Q66p ; congestive heart failure ; humans
salt loading ; uninephrectomy ; ANG II infusion mouse ; cardiac function ; mice ; HF
Mena expression ; HF ; mena ; cardiac pathophysiology
LVEF ; long-term mortality ; hospitalization ; acute decompensated HF
Fontan failure ; circulatory derangement ; hemodynamic ; portal hypertension ; cardiac output
HF ; index AMI ; hazard ratio
systolic heart failure ; spironolactone
uPR ; na+ channel mRNA splice ; cardiac ; na+ current ; human HF
diuretic efficacy ; neurohormonal activation ; fluid overload
BETs ; transcriptional pause release ; transcription ; pathological stress
lVAD ; transplantation eligibility status
LVEF ; LVEF
apoptosis ; pathogenesis ; heart failure
functional enrichment analysis ; programmed cell death
screening ; eCG ; older athletes ; atherosclerotic CAD ; sudden cardiac death
dose uptitration ; HR reduction
ANS mice ; LV fractional shortening ; lung weight
patients ; atrial fibrillation ; early treatment ; Atrial fibrillation ; Stroke prevention trial
frailty ; heart failure ;HF ; biological phenotype
functional MS ; valve plasty ; annular size reduction ; degenerative MR ; LV
idiopathic dilated cardiomyopathy
right ventricular ;RV ; body composition ; advanced heart failure ;HF
American college of Cardiology ;American Heart association ; evaluat ; management ; patients ;RAS
ARNI ; cardiovascular mortality ; hospitalization ; heart failure
peak work rate ; peak quadriceps force
implantable cardioverter-defibrillator deactivation ; physicians ; heart failure
EO-cFUs ; lower CD34+vegFR2 ; cells ; functional capacity ; nondiabetic patients
functional MS ; valve plasty ; degenerative MR ; LV
anaerobic metabolism ; respiratory
exercise training ; HF patients
myocardial DD ; muscle strip stiffness ; titin hypophosphorylation
NP measurement ; POc measurement ; NPs
etiology ; comorbidities
high-volume physicians ; readmission rates
RECENT FINdings ; perturbations ; intestinal morphology ; permeability ; absorption function ; CHF
proteins ; cardiac hypertrophy ; nucleolin
voordelen ; controlled randomized trials ; follow-up
Blood pressure ; arm cuff ; stroke volume ;SV ; ejection fraction ; end-diastolic volume ; echocardiography
Kansas City Cardiomyopathy Questionnaire ; kccq ; HF ; reduced EF ; patients ; HFpEF
biventricular support ; hybrid system ; HeartMate II lVAD ; CentriMag right ventricular assist device ; rVAD
tricuspid annular plane systolic excursion ; pulmonary arterial systolic pressure ; heart failure ; index ; right ventricular contractile
fibrosis ; heart failure ; myocardial tissue ; left ventricular tissue ; trichrome blue histologic analysis
bt ; DT ; cost-effectiveness
expenditure ; health per capita ; gross national income per capita ; HF ; la
borderline ; female ; preserved ; female
blood pressure control ; goal-directed lipid-lowering therapy ; smoking cessation ; RAS
SDQT ; HFVT ; HFVT ; HFVT ; hNorm group ; fixed-rate atrial pacing
simulations ; virtual cohorts
AF ; pharmaceuticals ; hFPEF
is ; cRT-d recipients ; heart failure ; death
bNP ; inhospital mortality
diffuse myocardial changes ; heart failure ; contrast agent ; breath-holding
Implantable cardioverter-defibrillators ;ICds ; cardiac resynchronization therapy ; cRT
ventricular assist device ;VAD ; extracorporeal membrane oxygenation ; ecmo ; renal function
Vascular endothelial growth factor blockade ; beta-blocker therapy ; cardiac function ; angiogenesis ; remodeling ; heart failure
NT-probNP ; plasma ; dyspnea ; left ventricular dysfunction ; admission ; ED
contractile function ; LV dilatation ; LV ; end-diastolic pressure ;wall stress ; lung weight
circulating progenitor cells ; cPCs ; endothelial repair ; cardiovascular
HF-acTION cohort ; hgb ; baseline HRQoL ; kccq
pathological remodelling ; heart ; cardiac hypertrophy ; HF ; fibrosis ; inflammation
Caucasian ; sNP rs10927887 ; ka renal chloride channel gene ;CLcnka
HFpEF ; echo-Doppler cardiography ; invasive haemodynamic assessment
LV remodeling ; diastolic properties ; XO inhibition
RAS- ; Î²-blocker uptitrations ; patients ; hFrEF ; HFpEF
cardiac magnetic resonance ; amyloidotic pattern ; multiple myeloma ; osteomedullary biopsy
DASh ; diastolic function ; ventricular-arterial coupling ; hypertensive heart failure ; preserved ejection fraction
Yorkshire swine ; pacemakers ; ventricularly paced ; induce heart failure
multiparametric echocardiographic score ; reverse remodeling ; cRT
isolated heart rate ;HR ; ivabradine ; systolic heart failure
biomedical treatment ; CHm ; biomedical treatment ; dCM ; heart failure
Cardiovascular Outcomes ; Renal Atherosclerotic Lesions ;coRAL ; stenting ; RAS
centrifugal flow pump ; hemocompatibility ; magnetically levitated rotor ; blood-flow paths ; artificial pulse
mitochondrial complex v activity ; aac ; phosphocreatine ; ATP
Mediterranean ; Dietary Approaches to Stop Hypertension ;DASh ; diet scores ; mortality ; postmenopausal women ;HF
therapeutic left-to-right interatrial shunting ; heart failure ; ejection fraction
mortality ; heart failure ;HF ; implantable cardioverter defibrillators ;ICds
Physician volume ; outcomes ; medically managed diseases ;HF
frail ; intermediate frail
eplerenone ; HF-REF ; hyperkalemia ; wRF
acute heart failure ; aHF
RM strategies
lb ; implantable cardioverter defibrillator-cRT
mDC
aberrant reactivation ; embryonic gene programs ; pathological heart disease ; transcription factors
hFPEF ; longitudinal outcome-monitoring phase ; cardiac event
sst2/low-dose BB ; sst2/high-dose BB ; cardiovascular events
skeletal muscle sarcomere structure ; heart failure ; type 2 diabetes ; epicatechin-rich cocoa
QRs morphology ; cardiac resynchronization therapy ; cRT
exercise-induced PASp ; pasp
heart failure ; severe hypertension ; mitral regurgitation ; mitral stenosis ; aggressive medical treatment ; heart failure
POc systems ; measuring NP levels
risk-adjusted mortality ; readmissions ; costs
lb ; QRs ; implantable cardioverter defibrillator-cRT
echocardiography ; cardiac diameters ; cardiac function ; vehicle-treated rats
electronic databases ; medline ; EMBAse ; PsycINFO
quality ; functional capacity
urban academic medical center
ST2 ; cardioprotective signaling ; myocardium ; biomarker ; heart failure ;HF
systolic HF ; cXL-1020 ; left ; right heart filling pressures ; systemic vascular resistance ; cardiac ; stroke
cardiovascular death ; stroke ; heart failure ; myocardial infarction
Cardiac-resynchronization therapy ; cRT ; morbidity ; mortality ; chronic systolic heart failure ; QRs
perk activation destabilized scn5a ; Kv4.3 channel mRNAs ; transient receptor potential cation channel m7 ;TRPM7) channel mRNA
implantable cardioverter-defibrillator ; Heart Function Clinic ; University Health Network ;Toronto
Exercise-induced PASp ; pulmonary hypertension patients ; ventricular contractile reserve
MI animals ; metoprolol ; plasma norepinephrine ; dopamine ; epinephrine
antagonists ; inhibitors ; renin-angiotensin-aldosterone ; sympathetic nervous systems ; CHF
inpatient assessments ; heart failure ; hospital discharge ; readmissions
antiplatelet agents ; anticoagulants ; vascular diseases
Fontan failure ; hemodynamically ; heart failure ; systemic vascular resistance ; sVR ; preserved cardiac index
myofiber dynamics ; myofiber shortening ; EMd ; dyssynchronous HF
crude ; adjusted ankle-brachial index ; pulse-wave velocity ; coronary artery calcium scores
truncated na+ channels activate ; unfolded protein response ; uPR ; electric remodeling ; HF
interagency Registry for Mechanically Assisted circulatory Support
international Right Heart Foundation Working Group ; defects ; right heart failure
cardiac hypertrophy ; pressure-overload ; abdominal aortic constriction ; aac
HF ; HF ; epidemiology ; SH ; c'd ; rheumatic fever
caloric restriction ;diet ; aerobic exercise training ;exercise ; exercise capacity ; QOL ; obese older patients ; hFPEF
chronic heart failure ;HF ; hemodynamic disorder ; syndrome ; dysfunction ; molecular pathways
guideline-recommended medications ; patients with heart failure ; reduced ejection fraction
HFpEF ; diastolic filling time ; controlling heart rate
mice ; cardiac myocyte-specific Mena overexpression ;TTA ; tgtetMena ; cardiac pathology
allopurinol ; contractile function ; efficiency ; XO-mediated ROS effects ; myofilament
therapy ; comorbidities
therapeutic strategy ; AF ; severe heart failure ; financial burden
rehospitalization ; Medicare hospital claims ; Medicare ; post-acute care transfer policy
risk ; heart failure ; refill compliance ; etidronate ; alendronate
AT ; metabolic exercise ; cardiac ; kidney index score
physical activity ; cRF ; HF mortality
et ; HDL-mediated protective effects ; molecular pathways ; chronic heart failure ;CHf
physicians ; patients ; advanced heart failure
isolated heart transplant ; ecCT
follow up body weight ; FM ; fFM ;cc
r. Cluster analysis
ventricular ejection fraction ; left ventricular diastolic end diameter
eccentric versus concentric left ventricular hypertrophy ; heart failure ; preserved ejection fraction
left ventricular ejection fraction ; heart failure ; preserved ejection fraction ;HFpEF
Î²-adrenergic receptor blocker therapy ; myocardial perfusion ; neoangiogenesis ; failing heart
hgb ; kccq scales ; hgb ; exercise training ; HRQoL
bone morphogenetic protein ; rRNA transcription ; heterochromatic chromatin
dopamine ; nesiritide ; decongestion ; renal function
actin cytoskeleton ; mitochondrial function ; intermediate metabolism ; glycolysis ;gluconeogenesis ; citrate cycle
elevated resistin ; biomarker ; anthracycline-induced cardiotoxicity ; heart failure ; macrophages
extracellular matrix ; left ventricular biopsies ; tissueFAXs technology
systolic HF ; Danish Heart Failure database ; ESRD ; Danish Registry on Dialysis
left ventricular assist devices ; lVADs ; patients ; advanced heart failure ; pump dysfunction ; pump replacement
bNP ; diastolic dysfunction
hART ; HFpEF ; HF ; reduced ejection fraction ;HFrEF
systolic function ; HFpEF patients ; long axis function ; exercise
concurrent HF ; odds ratio ; 28-day mortality ; hazard ratio
AAs ; HF ; hyperkalemia ; hypokalemia ; spironolactone
g-protein-coupled receptor kinase-2
NT-probNP assay ; nonterminal epitopes ; glycosylated
scn5a ; AngII ; hypoxia ; uPR ; downregulation ; na+ current
ST2 ; amino-terminal ; natriuretic peptide
sst2/high-dose BB ; sst2 ; low-dose BB ; cardiovascular event
anemia ; iron deficiency ; medline ; cochrane Library
neurohormones ; adipokines ; body composition ; CC ; fat free mass ;FFm ; fat mass ;FM
restoration ; cardiac plasma membrane ; s1PR1 ; overstimulation ; heart failure
Sprague- dawley rats ; sham ; aCF ; allopurinol
myocardial collagen ; myocardial delayed enhancement imaging
saxagliptin ; sitagliptin ; follow-up
fully magnetically levitated lVAS ; mortality ; Seattle Heart Failure model-predicted survival
performance ; hospitals
kccq domains ; internal consistency ; patients ; HFpEF ; cronbach
implantable cardioverter defibrillator-cRT ; non-LBbb ; QRs duration
mechanisms ; diagnostic approaches ; clinical trials
alendronate- ; etidronate- ; raloxifene-treated
chemotherapy ; trastuzumab ; comorbidities ; CHF ; international Classification of Diseases ; healthcare Common Procedure coding system codes
contemporary heart failure ;HF ; therapies ; HF ; preserved left ventricular ejection fraction ;LVEF
conscious dogs ; tachypacing-induced HF ; contractility ; end-systolic elastance ; venoarterial dilation
cr group ; control group ; hazard ratio
transplantation ; consultation
cox proportional hazards models ; death ; transplantation ; LV assist device implantation ; heart failure hospitalization
Nicorandil ; phosphocreatine ; adenine nucleotides ; mitochondrial oxidative phosphorylation capacity ; creatine kinase
intraclass correlation coefficient ; icc ; kappa coefficient ; standard error ; detectable change ; mDC
Risk ; Hospitalized Heart Failure ; Saxagliptin ; sitagliptin ; antihyperglycemic Drugs
race ; exercise training ; chronic heart failure ; Heart Failure ; controlled trial Investigating Outcomes in Exercise TraiNing ;HF-acTION
biomedical treatment ; CHm ; biomedical treatment ; dCM ; heart failure
Swedish national inpatient Registry ; rehospitalization ; stroke ; myocardial infarction ; heart failure ; caBG
Biventricular pacing ;BiVP ; cardiac output ;co ; cardiac surgery patients
New York Heart association ;NYha ; chronic heart failure ; reduced ejection fraction ; Canadian special access programme
AlphaLISa immunoassays ; antibodies targeting the extreme n ; c termini ; circulating NT-probNP
creatinine ; bNP ; furosemide dose ; oxygen flow ; dobutamine ; norepinephrine
expression ; mistargeting ; altered regulation ; Rad Q66p ; rGK protein
Myocyte hypertrophy antecedent to heart failure ; gene expression
Catheter ablation ; AF ; compensated HFPEF ; left ventricular ;LV ; ejection fraction
Cardiology practices ; national Cardiovascular Disease Registry ; practice Innovation ; Clinical Excellence registry
congestive heart failure ; Midwestern state ; South dakota
sts HH ; TM ; medical support ; all-cause mortality ; discharged patients ; heart failure
surgically induced myocardial infarction ; heart failure rats ; bisoprolol ; vehicle
in-patient follow-up
CHF ; cardiac explant c-Kit+ progenitors ; mechanisms
tachycardia ; intravenous atropine ; cardiac vagal tone ; CHF-DNx ; CHF-INv
cardiomyocytes ; mechanical ; humoral stimuli ; myocardium
biological phenotype ; deficit index ; medical records
BB therapy ; sst2 measurement ; chronic heart failure
ESRD ; systolic HF ; eGFR
tAPse ; PASp ; length-force relationship ; RV function evaluation ; LV dysfunction
tunel assay ; apoptotic cells ; tunel-positive cells
functional efficacy ; pure Hno donor ; myocardial function ; HF
biventricular support ; rVADs
Peritoneal dialysis ;PD ; diuretic resistant volume overload ; heart failure ;HF
left-to-right interatrial shunting ; patients with heart failure ; reduced ejection fraction
hno donor ; cXL-1020) isolated myoctyes ; intact hearts ; heart failure ;HF
bmi ; weight ; heart rate ; rhythm ; lying ; standing blood pressure ; auscultation ; valvular disease ; pulmonary congestion
myocardial extracellular matrix ; cardiac magnetic resonance T1 mapping ; pathobiology
aldosterone antagonist therapy ; chronic advanced heart failure patients ; post-myocardial infarction heart failure patients ; reduced ejection
Nicorandil ; decrement ; heart rate ; aortic blood flow ; mitochondrial oxidative stress ; doxorubicin cardiotoxicity
heart failure ; left ventricular ejection ; spironolactone ; Kaiser Permanente Northern California
SDQT ; HFVT ; hNorm group ; Î²-adrenoceptor blockade ; esmolol
heart failure ; CHARM programme ;Candesartan in Heart Failure Assessment ; Mortality ; Morbidity
heart failure ; preserved ejection fraction ; hFPEF ; heart failure ; overweight ; obese
Renal dysfunction ; heart failure ;HF ; renal disease ;ESRD
echocardiographic score ; LV reverse remodeling ; LV end-systolic volume
Peripheral artery disease ;PAD ; heart failure ;HF ; HF ; patients ;PAD
STUDY DESIGN ; readmission rates ; heart failure ;HF ; acute myocardial infarction ;AMI ; pneumonia
peripheral muscle pump ; cardiac filling ; subpulmonary ventricle ; Fontan circulation
renal dysfunction ; cardiovascular events ;stroke ; myocardial infarction ; heart failure ; coronary artery bypass grafting
asymptomatic pediatric Fontan ;PF ; catheterization
MS ; subvalvular ; dynamic ; annular MS ; fixed ring size
ventricular assist devices ; cardiac nurses ; management ; gastrointestinal bleeding
Lancet ; Anoop Shah ; air pollution ; heart failure ; morbidity ; mortality
anemia ; HF ; health-related quality of life ;HRQoL ; HF
cell therapy ; chronic heart failure ;CHF ; explant-derived progenitor cells
mRI-based models ; dyssynchronous nonfailing ; HF canine electromechanics
American college of Physicians ; aCP ; anemia ; iron deficiency ; heart disease
exercise ; cell senescence ; active ; malignancies ; cancer ; prostate ; colon ; osteoporosis ; depression ; dementia
drug-free
race ; chronic heart failure ;HF ; exercise training
capillary ; coronary perfusion ; ad-flk rats ; b-treated ; ad-c rats
physician volume ; mortality ; internists ; cardiologists
shuttle walk test ; body mass ; hand grip strength
protocol-driven POc testing ; NP ; patient consultation ; ED
Troponin T ; n-terminal pro-b-type natriuretic peptide ; biomarker ; heart failure risk ; atherosclerosis
tachycardic response ; methylatropine ; vagal tone ; bradycardic response ; propranolol ; sympathetic tone
acute RV failure ; chronic pulmonary arterial hypertension ;PAh ; acute pulmonary embolism
cardiac resynchronization therapy ; cRT ; mild heart failure ;HF ; QRs prolongation ; ejection fraction ;EF
Fractional flow reserve ; positron emission tomography imaging ; ischemia ; bottleneck stenting ; left ventricle ; proximal LAD
mitochondrial oxidative phosphorylation capacity ; creatine kinase activity ; oxidative stress markers ; DNA fragmentation
cox regression ; spironolactone ; death ; hospitalization ; severe hyperkalemia ; kidney injury
mortality ;hospitalization ; mortality ; cardiovascular mortality ;HF hospitalization ; cox ; exercise training
cardiac transplant ; ecCT ; transplant pool ; donors ; recipients
Exercise ; Medical Therapies ; Cardiac Function ; Shortness ; Breath Due to Lung congestion
septum ;systolic ; thickness ; LV posterior wall thickness ; LV internal diameter ; metoprolol
obese older patients ; hFPEF ; caloric restriction ; aerobic exercise training ; VO2
economic analysis ; Patient Management Interventions in Heart Failure ; cost-effectiveness ; disease management programs in heart failure
HF registry ; dichotomized patients ; HF ;EF ; HFpEF ;EF
BAT ; n-terminal pro-brain natriuretic peptide ; HF
HR variability ; mortality ; AMI ; CHF ;LV dysfunction
neprilysin inhibitors ; natriuretic peptide system ; atrial natriuretic peptide ; natriuretic peptide
postoperative survival ; patients ; preoperative hypoalbuminemia ; albumin concentration
acute RV failure ; pulmonary embolism ; mortality
elektrial activation ; dyssynchronous heart failure ;HF ; electromechanical behavior ; heart
patients ; advanced heart failure ;heart team ; cardiologists ; cardiovascular surgeons
Baroreflex sensitivity ; time domain heart rate variability ;HRV ; CHF-INv group ; sham-INv ; sham levels ; renal DNx
bisphosphonates ; alendronate ; etidronate ; risk ; heart failure
nurse assessment ; cognitive impairment ; hospitalization ; physician ; discharge ; elderly patients hospitalized ; heart failure
HF-acTION ; patients ; HF ; ejection fraction
Chinese herbal medicine ;CHm ; adjunctive treatment ; dilated cardiomyopathy ;DCm ; heart failure
serum resistin ; women ; anthracycline-containing chemotherapy ; cardiotoxicity
sst2 titrated to high-dose BB ; cardiovascular event rate
Rad Q66p ; cardiomyopathy ; mechanism
ventricular structure ; both geometry ; fiber ;sheet orientation ; handling ; slowed conduction ; wall stiffness
SDQT-to-SDRR ratio ; HFVT ; HFVT ; hNorm
renin-angiotensin system blocker ; beta-blocker therapy ; heart failure ; preserved left ventricular ejection
Functional electrical stimulation ; peripheral muscles ; endothelial function ; heart failure patients ; preserved left ventricular ejection fraction
cardiac transplant survival ; ecCT
diastolic dysfunction ; pathophysiology ; HFpEF ; non-diastolic abnormalities ; cardiovascular function
deranged ca(2+) handling ; EMd ; dyssynchronous HF
hypertension ; compensated HFPEF ; DASh ; srd ; sodium ; kcal
doxorubicin-induced cardiotoxicity ; Hum-Retn mice ; littermate controls ; human resistin ; retn
arrhythmia substrate ; AMI ; HR variability ; arrhythmia events
heart failure ;HF ; non-HF populations ; dietary patterns ; outcomes ; HF
HF ; AMI ; pna ; mortality
hypertension ; diabetes mellitus ; systolic ; diastolic murmurs
TAPse ; PASp ; nonsurvivors ; hFrEF ; HFpEF
epigenetic ;writer ; proteins ;histone acetyltransferases ; epigenetic ;erasers ;histone deacetylases ; cardiac development
NT-probNP ; mortality ; acute HF
haematopoietic cell transplantation ; hCT ; congestive heart failure ;CHf ; pre-hCT exposure to anthracyclines
cardioprotective effect ; nicorandil ; hemodynamic alterations ; mitochondrial dysfunction ; cumulative administration ; doxorubicin
in vivo inhibition ; mir-25 ; antagomir ; spontaneous cardiac dysfunction ; murine myocardium to heart failure
carvedilol ; nonselective Î²-blocker ; Î²-blocker metoprolol ; thromboembolic events ; heart failure
cox regression models ; propensity score decile ; oral glucocorticoid dosage ; HF hospitalisations ; loop diuretics
preoperative albumin ; mortality ; lVAD implantation
dyssynchronous HF ; electromechanical delay ;EMd ; myocyte depolarization ; myofiber
Beta blockers ; mortality ; readmissions ; heart failure ; ejection fraction ;HFrEF ; heart rate ;HR
reoperation ; bleeding ; driveline infection ; gastrointestinal bleeding ; debilitating stroke
dialysis patients ; HF hospitalization ; hospitalization ; mortality ; HF
Functional electrical stimulation ; fes ; exercise capacity ; emotional stress ; endothelial function ; chronic heart failure ; systolic function
ejection fraction ; cardiac index ; inotropes ; inotrope-dependent
systolic heart failure ; QRs ; cRT ; hospitalization ; heart failure
hoge-density lipoprotein ;HDL ; endothelial-protective effects ; endothelial cell ; ec ; nitric oxide ;NO
8-fluo-cAMP binding ; wild type ; phosphomimic Ser77 ; Ser83 mutant ; RIÎ± proteins ; double mutant ; wt RIÎ±
admission to discharge ; older adults ; heart failure ;HF ; Nursing Outcomes Classification ;NOc
insulin resistance ; type 2 diabetes ; insulin receptor substrates ;IRs1 ; iRS2 ; insulin-signaling components ; cellular metabolism
degs ; non-ischemic ; ischemic heart failure ; healthy control ; heart failure
hHF ; saxagliptin ; sitagliptin ; antihyperglycemic agents
QRs morphology ; cardiac resynchronization therapy ; resynchronization-Defibrillation ; Ambulatory Heart Failure trial ;RAFt
heart magnetic resonance imaging ; chelation choices ; patient compliance ; heart failure ; arrhythmias
volume EDs ; discharge patients ; heart failure home ; low-volume ED cases ; readmissions ; repeat ED visits
anticoagulation ; rate control ; cardiovascular complications ;stroke ; cardiovascular death ; acute heart failure ; atrial fibrillation ;AF
nitroxyl ; hno ; donor ; Angeli's salt ; inotropic ; lusitropic ; vasodilator effects ; cAMP
Gene expression ; Bax ; bcl-2 mRNA expression ; heart failure ; bcl-2/Bax
cPCs ; early-outgrowth colony-forming units ;EO-cFUs ; circulating CD34 ; vEGFR2 ; CD133
ejection fraction ;EF ; pre-PD ; NYHA class IIIb ; right ventricular dysfunction
continuous-flow lVADs ; heartMate II ;HM II ; HeartWare ; bt ; DT
undiagnosed heart disease ; symptoms ; HF
cRT-d ; IE ; IC ; cRT-d ; IEs
frailty ; biological phenotype ; weak grip strength ; physical exhaustion
transplant ineligible patients ; PD ; HF volume management
abnormal liver texture ; nodularity
biomarker studies ; biomarker-guided clinical trial ; multimarker-based strategy
right atrial myxoma ; massive embolism ; pulmonary arteries ; right atrial mass removal ; pulmonary embolectomy
acute right heart failure ; therapy refractory cardiogenic shock ; heart team ; extra corporeal membrane oxygenation ; ecmo ; cPR ;ICU
cardiac VEGF expression ; Akt ; endothelial no synthase activation ; failing hearts
heart failure ; left ventricular systolic dysfunction ; BB
post-DASh ; srd brachial ; central blood pressure ; radial arterial tonometry ; cardiovascular function ; echocardiographic
cardiac insulin-resistance ; aac ; insulin-stimulated rates ; glycolysis ; glucose oxidation ; plasma membrane translocation ; glucose transporter
Gene expression profile ; gse9128 ; Gene Expression Omnibus ; non-ischemic heart failure samples ; ischemic
exercise-induced PASp ; right ventricular contractile reserve ; pasp
Gene expression profiling ; cultured cardiomyocytes ; jq1 ; drug abrogated ; phenylephrine-induced genes
Psychosocial Factors ; Exercise Adherence ; Heart Failure Patients ; Insights ; Heart Failure ; trial Investigating Outcomes ; Exercise Training ;HF-acTION
ST2 ; functional capacity ; ambulatory patients ; HF
EF ; EF ; blinded core laboratory
cardiovascular diseases ; heart failure ;HF
bNP ; inhospital mortality
Quality of life ; all-cause mortality
DASh diet scores ; mortality ; HF ; Mediterranean diet scores
skeletal muscle mass ; appendicular lean mass index
CLcnka polymorphism ; p. arg83gly ; heart failure ; glomerular filtration rate ; reNAStur
intubation rates
black race ; patients ; chronic HF ; modifiable risk factors ; lower exercise performance ; HF hospitalization ; mortality ; exercise training
hearts ; fish lacking nucleolin ; chamber patterning ; functional deficits ; cardiac looping ; myocyte differentiation
fat ; lean mass ; fat loss ; enhanced catabolism ; adipose tissue ; cardioprotective ; HF
guideline-recommended drugs ; heart failure ; chart review ; biomedical reasons ; nonprescribing
hFrEF ; respiratory gas analysis
hearts ; tgtetMena mice ; wild-type littermates ; heart mass ; transgenic mice
raloxifene ; mechanism of action ; heart failure
derivation cohort ; coronary angiography ; systolic HF ; unclear etiology
arterial elastance ; ea ; end-systolic elastance ; ees ; ventricular-arterial coupling ; ratio ees ; ea
heart failure ; left ventricular ejection fraction ; fes ; exercise capacity ; emotional status ; endothelial function ; HFpEF
extracorporeal life support ; bridging therapy ; ischemic right heart failure ; refractory cardiogenic shock ; reperfusion therapy
HF with reduced ejection fraction ;HFrEF ; treatment ; HF met preserved ejection fraction ;HFpEF
Cells ; angiotensin II ;AngII ; hypoxia ; activators ; abnormal scn5a mRNA splicing ; overexpress scn5a variants
rhythm control therapy ; rhythm control therapy ; antiarrhythmic drugs ; catheter ablation ; electrocardiographic device
expenditures ; noncardiovascular diagnoses ; implantable cardiac arrhythmia devices ; noncardiovascular drugs
follow-up visits ; readmissions
contractility ; ventricular-arterial coupling
power spectral analysis ; low-frequenncy ;high-frequenncy ;LF ;HF ; CHF-inv ; sham-INv ; sham levels ; DNx

cardiac magnetic resonance ; postcontrast ; hFPEF ; biomarker ; hFPEF
myocardial DD ; collagen deposition ; titin modification ; obese ; diabetic zSF1 rats ; heart failure ; preserved ejection fraction
HF-acTION ; left ventricular ejection fraction ; New York Heart association ; IV HF
adverse event rates ; acute myocardial infarction ; congestive heart failure ; in-hospital adverse events
natriuretic peptide ;NT-probNP ; misdiagnosis ; heart failure ;HF
Macrophages ; cardiomyocytes ; Hum-retn mice ; doxorubicin in vitro ; hRetn ;human resistin ; mRNA ; protein expression
plasma collected ; HF patients ; immunoreactive ; NT-probNP
EH ; HFpEF ; HF ; reduced EF ;HFrEF ; hFrEF therapy
sympathetic tone ; parasympathetic tone ; heart rate response ; metoprolol ; atropine
FM ; plasma NPs ; total adiponectin ; FM ; fFM ; NPs ; adiponectin
lVADs ; CF devices ; HeartMate II devices ; Thoratec Corp ; Pleasanton ; Calif ; hVAD devices ; HeartWare intl ; intl ; Framingham ; Mass
beat-to-beat QT interval ; eCGs ;atrial pacing ; esmolol ; isoprenaline ; atropine infusion
CAD ; angiography ; systolic HF
frailty ; Health ABC Short Physical Performance Battery ; hABC Battery ; Gill index ; incident HF
HF ; QRs prolongation ; LVEF ; cRT ; reverse remodeling ; LV systolic dysfunction
HF ; t2d ; ERC ; treadmill testing ;VO2max ; oxygen consumption ; Skm biopsies
percutaneous revascularization ; angioplasty ; stenting
gastrointestinal bleeding ; incessant ventricular tachycardia storm ; terminal heart failure
load-corrected chronotropic response ; heart rate ; follow-up tests
transcriptional analysis ; cardiac tissue ; mice ; TAC- ; sham-operated ; jq1 ; vehicle ; BET inhibition ; pathological cardiac gene expression programme
epigenetic readers ; cardiac biology ; cardiac gene control ; chromatin-dependent signal transduction ; pathological gene expression ; HF progression
cox-proportional hazard models ; negative binomial regression models
heart failure ; sudden death ; noncardiac ; cardiac transplant
Peak oxygen consumption ;VO2max ; resting HR
cutoff value ; admission NT-probNP ; patients admitted to ED ; acute HF diagnosis
conditional gene-targeted hand2 mice ; pressure-overload-induced hypertrophy ; fibrosis ; ventricular dysfunction ; fetal
systolic blood pressure ; left ventricular ;LV ; hypertrophy ; AT ; AN ; AS ; ANS
RV support ; lVAD insertion ; cardiogenic shock ; myocardial infarction ; chronic decompensated heart failure
PF cohort ;New York Heart Association classes
HF ; AMI
diagnosis ; heart failure

Western Australian linked administrative health ; patients ; HF hospitalized ; index ; AMI
high-volume physicians ; mortality ; low-volume physicians
comanagement ; patients
nursing-sensitive outcome measures ; science ; effective treatment ; older adults hospitalized ; HF
free-breathing pulse sequennce ; myocardial t1 ; swine model ; tachycardia-induced heart failure
non-frail participants ; severe frailty ;HR ; Gill index ; HF
died ; non-survivors
Chronic Î²-AR stimulation ; catecholamine infusions ; rats ; pde2 expression ; cAMP hydrolytic activity ; blunted cardiac Î²-AR responsiveness
Xanthine oxidase ;XO ; rat ; left ventricular ;LV ; myocytes ; volume overload ;VO ; mitral regurgitation ; aortocaval fistula ;acf
obese ; zSF1 groups ; heart failure ; preserved ejection fraction ; lung weight ; preserved left ventricular ejection fraction ; left ventricular DD
chronic PAH ; hospitalized patients ; RV decompensation ; pharmacologic therapies ; RV failure management ; pAH
Chronic heart failure ;CHf ; multisystem disease ; anemia ; insulin resistance ; autonomic dysbalance ; cardiac cachexia
heart failure ; preserved ejection fraction ;HFpEF
inhibitor JQ1 ; BETs ; chromatin ; downstream signalling ; RNA polymerase II ;Pol II
ischemic-hypertensive cardiomyiopathy ; angina ; inducible myocardial ischemia ; coronary arteries
intestinal dysfunction ; disturbed intestinal barrier ; chronic inflammatory state ; catabolic ;anabolic imbalance ; cardiac cachexia ; CHF
RA ; methotrexate ; tNF antagonist ; non-biological disease modifying antirheumatic drug ;nbDMARD
diminished cyclic adenosine monophosphate ; cAMP ; augmented cyclic guanosine monophosphate ; cgMP ; failing hearts
cox proportional hazards regression modeling ; risk factors ; IE ; hospitalization ; acute coronary syndromes ; coronary interventions
miRNAs ; noncoding RNAs ; binding ; messenger RNA ; degradation ; translational repression
catheter ablation ; atrial fibrillation ;AF ; heart failure ; preserved ejection fraction ; hFPEF
HFpEF ; ivabradine ; ivabradine
mortality ; healthcare utilization effects ; combinatied care management ; telehealth ; congestive heart failure ; chronic obstructive pulmonary disease ; diabetes mellitus
heart failure ;HF ; acute myocardial infarction ;AMI ; pneumonia ; pNA
pathophysiology ;HF ; medical management ; pathophysiologic
ps ; pulmonary embolism ; diabetes ; chemotherapy
Cardiac c-Kit ; cells isolated ; cardiac explant-derived cells ; cardiac functions ; myocardial infarction
sphingosine-1-phosphate receptor ; s1PR ; Î²1-adrenergic receptor ;Î²1AR ; g-protein-coupled receptors ; heart
EF ;LCx model ; LAD ; stenting ; infarcted left ventricle ; LCx ; LAD
signalling cascades ; microRNAs ; bHLh transcription factor ; hand2 ; postnatal mammalian myocardium ; embryonic gene programs ; heart failure
BET ; bromodomain proteins ;BETs ; acetyl-lysine reader proteins ; HF
cardiac function ; echocardiography ; diastolic dysfunction ; e/e ; systolic dysfunction ; ejection
hART ; New York Heart Association ;NYHA ; hospitalized ; HF ; self-management counseling ; death ; HF hospitalization
mva ; surgical ring implantation ; leaflet motion ; leaflet resection ; edge-to-edge anastomosis
EH ; LV compliance ; CH ; end-diastolic volume ; LV ; end-diastolic pressure ; Î² coefficient
e-septal correlated ; pcWP ; e/e'lateral ; e/e'mean
Rad Q66p ; inhibitory actions ; Rad on cav1.2 ; cav1.3 ; l-type channel isoforms ; heart
inappropriate therapy ; atrial fibrillation ; carvedilol ; metoprolol
ERC induced recovery ; DAPc protein levels ; sarcomeric microstructure ; markers ; Skm growth ;differentiation ; myofibre regeneration
gLS ; LVEF ; sa ; CV events ; prognostic benefit ; echocardiographic systolic parameters ; AF
cPG-recommended pharmacological treatment ; device consideration ; left ventricular function assessment
Nordic walking ; standard cardiac rehabilitation ; functional capacity ; patients ; moderate to severe heart failure
Bradycardia induced ; intravenous metoprolol ; cardiac sympathetic tone ; CHF-INv rabbits ; sham-INv ; CHF-DNx
blood transfusions ; iron ; erythropoiesis-stimulating agents ; anemia ; congestive heart failure ; coronary heart disease ; transfusion
erythropoiesis-stimulating agent therapy
voltage-gated ca(2+) channels ; ventricular action potentials ; excitation-contraction ;EC ; coupling ; myocardium
heart failure ;HF ; tumor necrosis factor ;TNF ; tNF antagonists ; HF
AT ; oxygen uptake ; metabolic exercise ; cardiac ; kidney index score ; HF index
clinical ; genetic ; CHF predictive model ; curve ;AUc ; genetic ;AUc ; clinical
percutaneous one-vesel model ; chronic myocardial ischemia ; stent coated ; polytetrafluoroethylene tube
black race ; mortality ;hospitalization ;hazard ratio ;HR ; cardiovascular mortality ;HF hospitalization
Centers for Medicare and Medicaid Services ; cMS ; hospital quality of care outcomes ; risk-standardized mortality ; readmission rates ; penalties
Î²-blockade ; disease progression ; cAMP-dependent protein kinase ; pka ; Î²-adrenergic receptor activation
right heart circulatory failure ; mechanisms of disease ; right heart
HF
Grading of recommendations assessment ; Development and Evaluation ;GRADe
aldosterone antagonism ; heart failure ; aldosterone ; neurohormone ; electrolytes ; heart failure ; systolic dysfunction
AT1 receptors ; neprilysin blocks ; renin-angiotensin-aldosteron ;RAS ; vasodilatory ; diuretic effect ; natriuretic peptides
bNP ; glomerular filtration rate ; hypertension ; transmitral e-wave ;early diastolic mitral annular velocity
ivabradine ; exercise capacity ; left ventricular filling ; heart failure ; preserved ejection fraction ;HFpEF
medication ;nonadherence
HR variability/turbulence ; HR variability/turbulence ; cardiac patients
dopamine ; low-dose nesiritide ; renal function ; acute heart failure ; renal dysfunction
scientific literature ; HM II ; HeartWare patients ; economic evaluations ;HM II ; simulation models
risk of death ; glomerular filtration rate
creatinine ;hazard ratio ; post-transplant mortality
lVAD ; albumin levels ; hypoalbuminemia
pathophysiological origin
cox proportional hazard models ; follow-up ; physician ; discharge ; death ; urgent all-cause readmission
logistic regression analysis ; severe CAD ; diameter stenosis ; left main ; 3-vessel CAD ; 2-vessel CAD ; proximal left anterior descending artery
incidence ; mortality ; heart failure ; acute myocardial infarction ; Western Australia
Randomized aldactone Evaluation Study ; chronic advanced heart failure patients ; aldosterone antagonist ; spironolactone ; mortality
annular size reduction ; surgery ; diastolic mitral valve tethering ; anterior leaflet opening ; posteriorly displaced papillary muscles ; left ventricular dilatation
hypertensive HFPEF ; sodium-restricted DASh diet ; ventricular diastolic function ; arterial elastance ; ventricular-arterial coupling
signal transduction cascade ; transcription factors ; cardiomyocytes ; transcription factors ; epigenetic ; chromatin structure
CHF ; hCT ; polymorphisms ; anthracycline metabolism ; iron homeostasis ; anti-oxidant defence ; myocardial remodelling
ECs ; HDL ; phosphorylation ; eNOS-Ser ; eNOS-Thr ; PKc-Î²II-Ser
cRT on assignment ; time to death ; first HF hospitalization ;hazard ratio ; LVEF
animals ; heart failure ; histologically ; myocardial collagen ; tissue ; control ; heart failure
administratie databases ; Alberta ; discharged alive ; hospital ; heart failure
mouse ventricular myocytes ; sarcomere shortening ; ca(2+) transient
rCTs ; sts ; HH ; HM ; sts ; TM
pasp
lVAD therapy ; transplantation eligibility status ; device ; bt ; DT ; medical therapy
beta1-adrenergic receptor ; sphingosine-1-phosphate receptor ; s1PR ; reciprocal downregulation ; cardiac hypertrophic response ; progression to heart failure ; s1PR1 cardiac gene therapy
diagnostic ; radial artery tonometry ; p ; ICU
cardiomyocytes ; pde2 activity ; cgMP synthesis ; nitric oxide donors ; pde2 inhibition ; Î²-AR responsiveness
ejection fraction ; natriuretic peptide levels ; patients hospitalized with heart failure ; inhospital outcomes ; Guideline-Heart Failure Registry
breast cancer patients ; full Medicare coverage ; diagnosed ; stage I-III breast cancer ; chemotherapy ; sEER-Medicare ; Texas Cancer RegistryâMedicare databases
eRK1/2 signalling ; signalosome complex ; scaffold protein ; kinases ; sequential phosphorylation
magnetically levitated centrifugal-flow chronic lVAS
l-dko mice ; cardiac IRS1 ; iRS2 proteins ; heart failure ; cardiac energy metabolism ; p38Î± mitogen-activated protein kinase
heart failure treatment
hospitals ; heart failure ;HF ; acute myocardial infarction ; pneumonia
carvedilol ; metoprolol ; implantable cardioverter-defibrillator therapy ; MADit-cRT trial ; Automatic Defibrillator Implantation ; Cardiac resynchronization Therapy
Caloric restriction ; aerobic Exercise Training ; Peak oxygen Consumption ; Quality of Life ; Older Patients With Heart Failure ; Preserved ejection Fraction
left ventricular assist devices ; lVADs ; chronic end-stage heart failure ;bridge to transplantation ; bt ; transplant-ineligible patients ; destination therapy
right ventricular-pulmonary arterial coupling ;pulmonary vascular resistance ; right ventricular ejection fraction
implanted left-to-right interatrial shunt ; haemodynamic outcomes ; heart failure
RR ; heart failure ; bisphophonates ; crude RR ; confidence interval ;CI ; adjusted hazard ratio ;HR
aCP ; restrictive red blood cell transfusion strategy ; trigger hemoglobin threshold ; hemoglobin levels ; hospitalized patients ; coronary heart disease
hoog-cost Medicare fee-for-service beneficiaries ; Centers for Medicare ; Medicaid Services
acute heart failure ; renal dysfunction ; dopamine ; low-dose nesiritide ; decongestion ; renal function ; diuretic therapy
Rhythm control therapy ; AF ; atrial structure ; function ; sinus rhythm ; delayed rhythm control ; rate control
kccq summary scores ; New York Heart association class ; HFpEF ; HF ; EF
nicorandil ; doxorubicin-induced heart failure ; rats ; hemodynamic perturbations ; mitochondrial dysfunction ; ultrastructural ; antitumor
physician adherence ; guideline recommendations in heart failure ; systematic review protocol ; Clinical practice Guideline ;CPg ; outcomes ; heart failure ;HF
HF ; body composition ; skinfold thickness ; dual-energy X-ray absorptiometry ; echocardiography ; blood testing
cardiac insulin-resistance ; mitochondrial oxidative metabolism ; cardiac hypertrophy ; energy deficit ; hypertrophy ; heart failure
economic analysis ; Patient Management Interventions in Heart Failure ; kosten-effectiveness ; disease management programs in heart failure
rGK ; rem ; rem2 ; Rad ; Gem ;Kir ; monomeric g proteins ; ventricular action potential duration ; EC coupling ; inhibit cardiac l-type channel activity
breathing control ; cardiac arrest ; humans ; pulseless ventricular fibrillation ;PVF ; cardioverter-defibrillator device
annular size reduction ; surgery ; diastolic mitral valve tethering ; anterior leaflet opening ; posteriorly displaced papillary muscles ; left ventricular ;LV
pathophysiology ; heart failure ; preserved ejection fraction ; hFPEF ; myocardial extracellular matrix accumulation
cox model analysis ; pasp ; exercise ; haard ratio ; peak o2 per kilogram ; pasp
Oral glucocorticoids ; dose-related gradient ; HF ; HR
HFPSI ; risk of death ; medical hospitalization ; HF clinic outpatients ; HF resources ; health systems
HR ; ivabradine group ; Ea ; TAC
Guidelines-Heart Failure ; HF patients ;EF ; borderline ;EF ; preserved ;EF
VO2 ; lean body mass ; thigh muscle ;intermuscular fat ratio
testosterone supplementation ; exercise rehabilitation ; CHF ; testosterone status
CHm ; adjunctive treatment ; dCM ; heart failure
carvedilol ; inappropriate therapy ; metoprolol
acetylcholinesterase inhibitor pyridostigmine ; sympathovagal balance ; cardiac remodeling ; cardiac function ; HF ; myocardial infarction
re-hospitalization
cardiac arrest ; cardiopulmonary resuscitation ; cPR ; posterior wall infarction ; cardiac centre
ambulatory patients ; heart failure ;HF ; ejection fraction ; rEF ; renin-angiotensin system ;RAS ; Î²-blockers
uPR ; scn5a ; ventricular systolic HF tissue samples ; human induced pluripotent stem cell-derived cardiomyocytes ;hiPSc-CMs
type 2 diabetes ; saxagliptin ; sitagliptin ; pioglitazone ; sulfonylureas ; long-acting insulin products
aCP ; erythropoiesis-stimulating agents ; anemia ; congestive heart failure ; coronary heart disease
hyperkalemia ; mineralocorticoid receptor antagonists ; race ; mineralocorticoid receptor antagonists ; heart failure ;HF
pde ; pde2 ; cgMP ; cAMP hydrolysis ; negative cross talk ; cgMP ; cAMP signaling
mitochondrial-targeted antioxidant ; protective peptides ; Szeto-schiller ;SS ; cardiac function ; proteomic remodeling ; signaling pathways
cardiac sympathetic activity ; i-meta-iodobenzylguanidine ; i-miBG ; Î²-blocker
tAPse ;longitudinal RV fiber shortening ; PASp ;force generated ; RV ; in vivo RV length-force relationship ; disclosing prognosis
coprimary end points ; cumulative urine volume ; decongestion end point ; serum cystatin C ; enrollment ;renal function
brain natriuretic peptide ; bNP ; bNP ; bNP
LVEF ; clinical composite response ; reverse remodeling parameters ; time to death ; HF hospitalization
Swedish Web-system for enhancement and Development of evidence-based care in Heart disease Evaluated According to Recommended Therapies registry ; stockholm
n-terminal probNP ;NT-probNP ; midregional proANp ;MR-proANp ; total adiponectin ; CHF ; bmi ; FM
MI ; hazard ratios ; HF
carvedilol ; von Willebrand factor ; metoprolol ; Î²2-adrenergic receptor haplotype
EC ; HDL ;NYha-IIIb ; phosphorylation ; eNOS-Ser ; phosphorylation ; eNOS-Thr ; HDL
HF ; HF ; EF ; HF ; HF ; preserved EF ; HF ; MI ; prevention strategies
ctnt ; NT-probNP ; aRIC HF model ;AUcs ; continuous NRIs
cardiovascular events ; sst2 status ; BB dose ; metoprolol succinate
Medicare ; older patients ; acute care hospital ; HF ; AMI ; pNA
cochrane Effective practice ; Organisation of Care Taxonomy
mouse heart failure ;HF ; hypertensive heart disease ; hHD ; pathophysiology ; therapeutic targets ; hHD
coPD ; CHF ; cRF ; ICC ; kappa coefficients
global left ventricular longitudinal systolic strain ; gLS ; left ventricular mechanics ; cardiovascular ;CV ; atrial fibrillation ;AF
implantable cardioverter-defibrillator deactivation preferences ; distressing implantable cardioverter-defibrillator shocks
heart failure ; myocardial function ; dilated poorly contracting ventricles
implantable cardioverter-defibrillator deactivation ; implant
stable heart failure ; left ventricular ejection fraction ; aerobic training ; dynamic resistance training ; lower limbs
mouse Rad Q65p ; murine equivalent ; human Rad Q66p ; l-type currents ; cav1.2 ; cav1.3 channels ; wild-type Rad
cRT ; control group ; hazard ratio ; 95% confidence interval ;CI
fit ; unfit ; cRF ; hazard ratios ; fit ; unfit ; overweight body mass index ; obese men
median age ; women ; median left ventricular ejection fraction ; median eGFR
cost ; rhythm-control
contextual factors ; patient preferences ; priorities ; guideline-recommended medications
ethically complex situations ; pediatrics ; families ; religious beliefs ; life-sustaining treatment
Medicare Patient Safety Monitoring system ;MPSMS ; adverse event rates ; patients hospitalized ; acute myocardial infarction ; congestive heart failure ; pneumonia ; surgery
sarcoplasmic reticular ;SR ; ca(2+)-uptake ; protein content ; SR ca(2+)-pump ; phospholamban ; infarcted hearts ; metoprolol
HFPSI model ; blood urea nitrogen ; natriuretic peptide ; New York Heart association class ; diabetes status ; atrial fibrillation ;flutter
Timed Up & Go ; tug ; advanced chronic obstructive pulmonary disease ;coPD ; chronic heart failure ;CHf ; chronic renal failure ;CRF
RM ; home telemonitoring ;TM ; implanted monitoring devices ; medical support ; structured telephone support ;STs ; human-to-human contact ;HH ; human-to-machine interface ;HM
heart failure ;HF ; plasma ; natriuretic peptide ; bNP ; reduced ; preserved ejection fraction ;EF ; HF studies ; sex
gLS ; left ventricular ejection fraction ;LVEF ; systolic mitral annulus velocity ; sa ; CV events
patients hospitalized ; HF ; LVEF ; long-term mortality ; LVEF
inmuscular testosterone supplementation ; chronic heart failure ;CHf ; low testosterone status
cox regression analysis ; beta-blockers ; beta-blockers ; inappropriate therapy ; antitachycardia pacing ; aTP ; shock therapy
m ; Minnesota ; quality of life
congestive heart failure visits ; ED visits
patients ; angiotensin-converting enzyme inhibitors ;angiotensin receptor blockers ; Î²-blockers ; heart failure ; ejection fraction
rats ; hearts ; caspase-3 activity ; phosphocreatine ; adenine nucleotides ; cytochrome c ; bcl2 ; Bax ; caspase 3 expression
rapid right ventricular pacing ; Bax ; bcl-2 ; Caspase-3 ; RTQ-PCr ; interventricular septum biopsies ; beagle dogs ; heart failure
sodium-restricted dietary approaches ; stop hypertension diet ;DASh ; srd ; left ventricular diastolic function ; arterial elastance ; ventricular-arterial coupling ; hypertensive HFPEF
medication ; physical therapy ; implantable defibrillators ; circulatory support ; transplantation ; heart failure
CD34+vegFR2+ cells ; functional capacity ; 10-cell ; CD34+vegFR2+ cells ; VO2
arginine vasopressin ; aVP ; physiologic processes ; CHF inhibition ; aVP ; vasopressin receptor antagonist therapy ; CHF
inpatients with heart failure ; reduced ejection fraction
aerobic ; resistance training ; augmented feedback ; exercise capacity ; muscle strength ; cardiac ;NT-probNP ; inflammatory ;IL6 ; hscrp
reversibility ; heart failure ; myocardial infarction ;MI ; Î²-adrenoceptor blockade ; infarcted rats ; metoprolol
Resting tension ;Fpassive ;sarcomere length relations ; muscle strips ; kcl-KI treatment ; titin ; extracellular matrix ; fpassive
CHF ; anthracycline exposure ; stem cell source ;allogeneic
crude 28-day case-fatality rate ; concurrent HF ; concurrent HF
hospital performance ; readmission metrics ; all-cause readmission ; acr ; Potential Preventable Readmission ; pPR ; Centers for Medicare ; Medicaid ; cMS
metoprolol ; carvedilol ; sympathetic activity ; von Willebrand factor
acute HF trials ; RELAX-aHF ; ASTRONAUT ; PRONTO
hospitalized HF ; international Classification of Diseases ; Ninth revision ; Clinical Modification codes ; discharge diagnosis
Pulmonary capillary wedge pressure ; hg ;SD ; pulmonary arterial pressure ; pulmonary resistance
Rad Q65p ; gating movement ; channels ; wild-type Rad ; Q65p substitution ; l-type channel inhibition ; rGK proteins
heart failure ; proteomics ; actin cytoskeleton pathways ; SS20 ; mitochondrial ; metabolic pathways
aortic insufficiency ;AI ; mechanical circulatory support ; continuous flow ;CF ; left ventricular assist devices ; lVADs ; pulsatile devices
pyridostigmine ; coronary artery ligation ; cardiac vagal ; sympathetic tone ; cardiac remodeling ; left ventricular dysfunction ; HF
follow-up visits
heart failure ; refractory ; terminal heart failure
heart failure discharges ; University of Connecticut health Center
New York Heart association ;NYha ; Class II Heart Failure ; eplerenone ; Placebo ; standard Heart Failure Medicines ;EMPhaSIS-HF Study
echocardiograms ; left ventricular base ; midpapillary ; apex ; IVc occlusion ; BiVP ; STE analysis ; twist ; apical ; basal rotations ; CS ; RS
drugs ; RAas ; direct renin inhibitors ; neutral endopeptidase inhibitors ; vasopeptidase inhibitors ; angiotensin receptor blockers
acute heart failure ;HF ; pharmacologic studies ; calcium-sensitizing agents ; antagonists ; endothelin ; vasopressin ; adenosine
HF induced in mice ; phenylephrine ; haemodynamic stress ; surgical method ; transverse aortic constriction ;TAC ; jq1 ; cardiac hypertrophy
muscle aerobic capacity ; postexercise phosphocreatine resynthesis ; Fontan adults
i-miBG cardiac washout ; carvedilol ; metoprolol treatment ; Î²2-adrenergic receptor haplotype
acute myocardial infarction ;AMI ; cardiac failure ;HF ; complicating AMI
h-dko ; ventricular mass ; cardiac apoptosis ; fibrosis ; Aktâforkhead box ; o-1 signaling ; cardiac metabolic ; ATP
bottleneck stent ; proximal left anterior descending ;LAD ; proximal circumflex artery ;LCX ; proximal LCX ; mid LAD
postmarketing ; hospitalized heart failure ;hHF ; dipeptidyl peptidase-4 ; dPP-4 ; antihyperglycemic agents
quality improvement database ; multivariable cox modeling ; Heart Failure Patient Severity index ;HFPSI ; University of Michigan HF clinic ;UM cohort
pde2 overexpression ; healthy cardiomyocytes ; cAMP levels ; ca2 ; inotropic effect ; Î²-AR stimulation ; basal contractility
inappropriate ATP ; inappropriate shock therapy
Cardiac resynchronization therapy ; cRT ; dialysis-dependent patients ; heart failure ;HF
cardiorespiratory fitness ;crf ; body mass index ; heart failure ;HF ; mortality ; cardiovascular risk factors ; HF mortality ; fit ; unfit men
eplerenone ; hyperkalemia ; renal function ; EMPHASIS-HF ; eplerenone in Mild Patients Hospitalization ; SurvIval Study in Heart Failure
Heart rate ;HR ; variability ; cardiac patients ; acute myocardial infarction ;AMI ; congestive heart failure ;CHf ; left ventricular ;LV
neonatal rat ventricular cardiomyocytes ; chronic insulin exposure ; iRS1 ; iRS2 proteins ; insulin action ; activation ; cardiac dysfunction ; insulin resistance ; type 2 diabetes
echocardiograms ; left ventricular midpapillary level ; atrioventricular delay ;AVd ; interventricular delay ;VVd ; STE analysis ; circumferential strain ;CS ; radial strain ;RS
New York Heart association ;NYha ; functional class III HF ; ejection fractions ; chronic stable guideline-directed medical therapy ;GDMT
non-LBbb ; QRs ; hazard ratio
abnormal Ca(2+) handling ; dyssynchronous HF ; myofiber shortening velocity ; septum ; myofiber shortening ; stretch rate ; lateral wall
label-free shotgun proteomics ; global proteomics ; transverse aortic constriction ;TAC-induced heart failure
c-Kit+ cells ; transforming growth factor-Î² ; tGF-Î² ; epithelial ; mesenchymal transition markers ; pluripotency markers ; shams
pka subunits ; type II regulatory ;RIiÎ± ; catalytic ; cÎ± ; subunit expression ; rIIÎ± ;Ser96) ; cÎ± ; phosphorylation ;HF
hFrEF ; left ventricular ejection fraction ; HFpEF ; left ventricular ejection fraction ; RAS- ; Î²-blocker dose changes ; index HF
g-protein-coupled receptors ; reciprocal regulation ; mouse hearts ; Î²-adrenergic receptor stimulation ; postischemic heart failure
concentric remodeling ;CR ; concentric hypertrophy ;CH ; left ventricular ;LV ; remodeling ; heart failure ; preserved ejection fraction ;HFpEF ; eccentric hypertrophy ;EH
weight ;SD ; diet group ;SD
RV dysfunction ;hazard ratio ; confidence interval ;CI ; cachexia ;hazard ratio
resting HR ; VO2max
tGF-Î² inhibition ; c-Kit+ cell phenotype ; function in vitro ; cardiac progenitor function ; cell expansion protocols
NT-probNP ; inflammatory biomarkers ; hscrp ; IL 6 ; hscrp
BETs ; neurohormonally induced heart disease ; nanomolar doses ; jq1 ; phenylephrine-mediated hypertrophy ; cardiomyocytes ; pathological gene induction
BAT ; functional status ; exercise capacity ; n-terminal pro-brain natriuretic peptide ; burden ; heart failure hospitalizations ; GDMT-treated NYHA functional class III HF
activation ; p70s6k ; PKc-Î²II ; malondialdehyde ; bound to HDL ;NYha-IIIb ; HDL ;healthy
MLHF total score ; exercise ; diet
nonpace ; non-DNx ; sham-Innervated ; sham-inv ; nonpace DNx ; sham-DNx ; pace non-DNx ; cmf-inv ; pace ; DNx ;CHf-DNx
hABC Battery score ; HF risk ; health ABC ; HF model ; SD decrease ; score ; controlled for death ; competing risk
ejection fraction ; frail ; biological phenotype ; risk of death ; frailty ; deficit index
hemoglobin ; hgb ; HRQoL ; HRQoL ; patients in Heart Failure ; trial Investigating Outcomes of Exercise Training ;HF-ACTION
Atrial Fibrillation ; congestive Heart Failure trial ; health care expenditures ; patients ; QuÃ©bec ; rhythm ; rate-control treatment strategies
heart failure ; myocardial ischaemia ; tachy- ; bradyarrhythmias ; valvular regurgitation ; pulmonary embolism ; infection ; renal dysfunction
calcineurin ; nfat signalling ; miR-25 expression integrate ; helix-loop-helix ; bHLh ; transcription factor dHAND ; hand ; diseased human ; mouse myocardium
Exercise time ; PSSS ; btes ; exercise time ; PSSS ; btes
NT-probNP cutoff point ; sensitivity ; confidence interval
prognostic power ; r-r interval oscillations ; non-linear HR variability ; fractal scaling exponent
diastolic function ; diastolic filling formalism ; relaxation ;viscoelastic ; passive ;stiffness ; doppler mitral inflow velocity ; e-wave
heart failure ;HF ; spontaneous ventricular tachycardia ;HFVT ; HF patients ; spontaneous VT ;HFVT ; structurally normal hearts ; hNorm
gLS ; cox model ; chronic heart failure ; hypertension ; diabetes ; prior stroke score ; glomerular filtration rate ; LVEF ; sa
ventricular assist device support ; ecmo ; extracorporeal membrane oxygenation membrane support ; ecmo ; VAD
ischemic events ;IEs ; ischemic cardiomyopathy ;IC ; cardiac resynchronization therapy ; defibrillator ; cRT-d
cost-effectiveness ; heart failure disease management programs ; evidence-based treatments
human resistin in heart failure ; humanized mouse ; murine resistin ; transgenic ; Retn gene ; hum-retn mice ; basal ; inflammation-stimulated resistin ; humans
angiotensin-converting enzyme inhibitors ;angiotensin receptors blockers ; Î²-blockers ; devices
tgtetMena mice ; cardiac injury ; ejection fraction ; fractional shortening ; heart dilatation ; hypertrophy ; transverse aortic constriction ;TAC
resynchronization-Defibrillation ; Ambulatory Heart Failure trial ; implantable cardioverter defibrillator-cRT ; cardiovascularverter defibrillator-cRT
heart failure patients ; Italy ; confirmatory factor analysis ; cfa ; SCHFI ;Self-Care Maintenance ; Self-Care management ; Self-Care Confidence
functional status ; wt ; NYha class ; patients ; HFpEF ; hFrEF ; therapy ; HFpEF ; HF hospitalization
renal dysfunction ; chronic obstructive pulmonary disease ; diabetes ; peripheral vascular disease ; left ventricular ejection fraction ; iCD shocks ; mortality ; ischemic cardiomyopathy
Raf-MEK1/2-erk1/2 scaffold proteins ; cardiac remodelling
CHF ; SD testosterone levels ; nmol/L
functional MS ; LV dilatation ; treatment for heart failure ;HF ; LV ; functional MS ; HF ; MR ; degenerative mitral valve
New York Heart association class ; kccq overall Summary ; Total Symptom domains ; Spearman correlations ; 2-way aNOVA ; patients ; HF ; EF ; HFpEF
angiotensin converting enzyme inhibitor ; angiotensin-receptor blockers ; Î²-blockers ; heart failure
c57b ; infusion ; ANG II infusion ; uninephrectomy ; ANG II infusion ; salt loading ; as ; ANG II infusion ; uninephrectomy ; salt loading ;ANS
early transmitral blood flow velocity ; tissue ; doppler ; early diastolic mitral annulus velocity ; pulmonary capillary wedge pressure ; pcWP ; decompensated systolic heart failure ;HF
systolic indices ;LV ejection fraction ; LV strain ;strain rate ; systole ; diastolic indices ; LV strain rate ; diastole ; early transmitral flow ; sinus rhythm
peak VO2 ; exercise ; body mass
age- and sex-adjusted risk ; hazard ratios ; confidence interval ;CI ; early-onset HF
AMI patient ; hospital ; best quintile ; performance ; hospital Compare
Mass spectrometry ; circulating NT-probNP ; physiological proteolysis ; leu3-Gly4 ; pro6-Gly7
ctnt ; NT-probNP ; laboratory report ; ctnt ; NT-probNP ; HF prediction model
HFpEF patients ; New York Heart Association class II ; ejection fraction
depressed left ventricular ;LV ; systolic pressure ; pressure ; ejection fraction ; fractional shortening ; cardiac output ; LV end-diastolic pressure ; MI animals ; metoprolol
baroreflex Activation Therapy ; Heart Failure With a Reduced ejection Fraction ; carotid baroreflex activation therapy ;BAT ; advanced heart failure ;HF
enrollment ; haard ratio ;HR
HF ; raised blood glucose levels ; obesity ; tobacco ; systemic hypertension ;SH ; rheumatic fever ; Chagas' disease ; c'd
cRF ; overweight ; obese body mass index
kccq ; patients ; HFpEF ;log rank ; EF
egFR group II ; egFR group III ; egFR group IV ; uncontrolled hypertension ; diuretics ; age ; ESRD
myocardial phosphodiesterase-2 ; pde2) ; heart failure ;HF ; pde2-mediated effects ; beta-adrenergic receptor ;Î²-AR ; cardiomyocytes
heart failure patients ; cardiac resynchronization therapy ; defibrillator ; implantable cardioverter-defibrillator device ; carvedilol ; ATP ; shock therapy ; metoprolol
epicatechin-rich cocoa ; Skm mitochondrial structure ; taub ; Ramirez-sanchez ; ciaraldi ; perkins ; Murphy ; naviaux ; Hogan ; ceballos ; Maisel ; Henry
follow-up visits ; death ; urgent readmission
mena overexpression ; TTA/tgtetMena mice ; TAC surgery ; cardiac hypertrophy ; TTA/tgtetMena ; post-TAC cardiac functional deterioration
echocardiography ; LV end-diastolic volume ; disappearance ; MR ; mitral valve opening ; mVA ; pressure gradient
PD ; diuretic refractory severe-end-stage HF
ATP production rates ; mitochondrial oxidation ; glucose ; lactate ; fatty acids ; myocardial glycolysis
eplerenone ; potassium ; potassium
New York Heart Association class III heart failure ;HF ; left ventricular ejection fraction ; permanent periodic breathing ; pb
bottleneck stent ; proximal LAD ; LCX ; porcine model ; reversible myocardial ischemia ;open stent ; ischemic heart failure ; stent
Potassium ; spironolactone ; non-AAs ; AAs
obese participants ;SD ; body mass index ; chronic ; stable HFPEF
proangiogenic effects ; B ; activation ; VEGF pathway ; rats ; intravenously injected ; adenoviral vector ; decoy VEGF receptor ; ad-flk ; control adenovirus ; ad-c
post- lVAD AI ; aortic valve oversewing ; leaflet repair ; bioprosthetic aortic valve replacement ; CF lVAD patients
exercise-induced pulmonary artery systolic pressure ;PASp ; stress ; doppler echocardiography ; right ventricular contractile reserve ; pulmonary hypertension ; right heart failure
medline ;EMBAse ; HEalthSTAR ; cINAHL ; cochrane Library ; Campbell Collaboration ; Joanna Briggs institut ; evidence Based practice ; Centre for Reviews and Dissemination ; evidence Based practice
systolic heart failure ; Î²-blocker ; angiotensin converting enzyme inhibitor ; angiotensin-receptor blocker
heart failure ; neuro-hormonal system ; angiotensin converting enzyme inhibitors ;angiotensin receptor blockers ; angiotensin converting enzyme inhibitors intolerance ; beta receptor blockers ; mineralocorticoid receptor antagonists
open chest model ; twist ; RS ; RS synchrony ; CS ; STE ; noninvasive surrogates ; RVPO ; RS synchrony ; CS ; BiVP ; CO
TAPse ; PASp ; tAPse-to-PASp ratio ;TAPSe ;PASp ; cox regression ; kaplan-meier analyses ; tAPse ; pasp
symptom limited ; cPET ; CHF ; control ; exercise ; exercise
Human heart failure ;HF ; mRNA splicing ; voltage-gated cardiac na+ channel Î±-subunit ; scn5a ; encoding truncated ; nonfunctional channels ; endoplasmic reticulum
paediatric heart failure ; myocarditis ; dilated cardiomyopathy ; heart failure ; cellular responses ; heart failure ; anthracycline treated survivors ; childhood malignant disease
Tools for Economic Analysis of Patient Management Interventions in Heart Failure ; kosten-efectiveness model
natriuretic peptides ;NPs ; b-type NP ; n-terminal pro-b-type NP ; acute heart failure ; Emergency Department ;ED ; acute dyspnea
peak oxygen consumption ;peak VO2 ;ven ; vco2 slope ; exercise oscillatory ventilation ; eOV ; partial pressure ; end-tidal CO2 ;PETco2 ; cardiopulmonary exercise testing
Denmark ; bisphosphonates ; raloxifene
hypertension ; LV dilatation ; LV dysfunction ; MR ; MS ; mitral valve ; closure ; opening ; organic lesion ; systolic ; diastolic tethering ; MR ; MS
tolvaptan ; severe hyponatremia ; Japan ; congestive heart failure patients ; optimal diuretic therapy ; sodium levels ; systolic function
longitudinal strain ; left ventricle ; echocardiographic measurements ; patients ; baseline echocardiography ; cRT ; follow-up echocardiograms
platelet-activating factor ;PAf ; metabolic enzymes ; heart failure ;HF
acute care surgery ;ACs ; oHT ; transplantation ; medical therapy ; mt ; intravenous inotropes ; ventricular assist devices ;VADs
ivabradine ; left ventricular filling pressure response ; exercise ; diastolic mitral flow velocity ; early diastolic mitral annular velocity
renin-angiotensin-aldosterone system ;RAas ; hFrEF ; angiotensin-converting enzyme inhibitors ; angiotensin receptor blockers ; aldosterone blockade ; HFpEF
lVET ; unfavorable outcome
heart rate ; blood pressure ; renal function ; spironolactone ; RAS blockers ; Î²-blockers
cardiac performance ; Î²-adrenoceptor blockade ; heart failure ; SR ca(2+)-pump function ; reverse cardiac remodeling ; plasma catecholamines
angiotensin-converting enzyme inhibitors ;angiotensin receptor blockers therapy ; Î²-blockers therapy
SS31 ; congestive heart failure phenotypes ; mitochondrial damage ;TAC ; mitochondrial proteome changes ; mitochondrial ; nonmitochondrial protein changes
myofibrillar ca(2+)-stimulated ATPase activity ; mRNA levels ; SR ca(2+)-pump ; phospholamban ; Î±-myosin heavy chain ; mRNA level ; Î²-myosin heavy chain ; metoprolol
HDL ; healthy controls ;HDL ; CHF-NYha-III ;HDL ;NYha-IIIb ; ET ; CHF-NYha-II ;HDL ;NYha-II
anestized dogs ; coronary microembolization-induced HF ; cXL-1020 ; left ventricular end-diastolic pressure ; myocardial oxygen consumption ; ejection fraction ; maximal ventricular power index
mDC ; mDC ; 95% confidence level ; mDC95%
heart failure ; t1-mapping values ; contrast agent
HF ; la ; idiopathic dilated cardiomyopathy ; c'd ; ischemic ; SH ; valvular ; alcohol
ST2 levels ; functional capacity ; ambulatory patients ; HF ; Heart Failure ; controlled trial Investigating Outcomes of Exercise Training ;HF-ACTION ; exercise training ; HF
cardiopulmonary exercise testing ; exercise rehabilitation ; patients ; chronic heart failure ;CHF ; CardioPulmonary Exercise Testing ; cPET ; exercise rehabilitation ; China
ischemic HF pathogenesis ; NYHA functional class IV ; glomerular filtration rate ; heart rate ; hypertension ; diabetes mellitus ; myocardial infarction
HF-acTION ; exercise training ; patients ; HF ; low left ventricular ejection fractions ; HRQoL ; Kansas City Cardiomyopathy Questionnaire ; kccq
cRT ; systolic dysfunction ; resynchronization reverses remodeling ; systolic left v entricular dysfunction ; reverse ; left ventricular ;LV ; ejection fraction ;LVEF
glomerular filtration rate ; egFR ; type 2 diabetes ; total cholesterol ; lDL-cholesterol ; CLcnka gg genotype
echocardiography ; LV ; end-diastolic dimension ; LV ; end-diastolic pressure ;wall stress ; lung weight ; untreated ACF groups ; sham group
e-lateral ; diagnosti performance ; s'lateral ; aUC
spironolactone ; risk ; hospitalization
Rate-control patients ; cardiac procedures ; cardioversions ; kosten ; antiarrhythmic drugs ;CAD ; ci
diabetes mellitus ; cardiomyopathy origin ; Î²-blocker ; angiotensin-converting enzyme inhibitor ; angiotensin II receptor blocker
eplerenone ; post myocardial infarction ; Heart failure Efficacy ; SUrvival Study ;EPHESUS ; post-myocardial infarction patients ; heart failure ; aldosterone antagonist eplerenone
carvedilol ; metoprolol ; inappropriate implantable cardioverter-defibrillator therapy ; MADit-cr ;Multicenter Automatic Defibrillator Implantation With Cardiac resynchronization Therapy
risk reduction ;HR ; 95% confidence interval
DASh ; srd ; brachial systolic pressure ; central end-systolic pressure
HF ; obese ; body mass index ; black ethnicity ; idiopathic-dilated cardiomyopathy
all-cause mortality ; hospitalization ; HF ; LVEF ; cardiac Failure Survey ; ISrael
left ventricular ejection fraction ; world health Organization criteria ; idiopathic dilated cardiomyopathy ; negative coronary angiography
europese society of Cardiology guidelines ; hFPEF ; heart failure ; preserved LV ejection fraction ; non-dilated left ventricle ; diastolic dysfunction ;impaired LV relaxation ; LV diastolic stiffness ; LV filling pressures
Î²1ARs ; s1PR1s ; myocyte ; cAMP production ; receptors ; regulatory ; g-protein-coupled receptor kinase-2
paf-cpt ; PAf ; lyso-paf-AT ; paf-AH ; lp-PLA2
heart failure ;mean ejection fraction ; cardiac rehabilitation ; Nordic walking
dRS-stratified hazard ratios ; ci ; sitagliptin ; pioglitazone ; ci ; sitagliptin ; sulfonylureas ; insulin
skeletal muscle mass ; t-score ; Fontan ; sarcopenic range ; muscle wasting ; t-score
testosterone group ; oxygen uptake ; Beck depression inventory ; leg strength ; Medical Outcomes Study Short-Form quality of life domains
RAS- ; Î²-blocker uptitrations ; all-cause mortality ; HF readmissions ; hFrEF ;hazard ratio ;HR
Heart Failure ; trial Investigating Outcomes of Exercise Training ;HF-acTION ; social support ; barriers to exercise score ; btes
ST2 ; cardiovascular death ; HF hospitalization ;hazard ratio ; all-cause mortality ; hazard ratios ; log2
New York Heart association ; Fontan adults ; cardiopulmonary exercise testing ; lean mass quantification ; dual x-ray absorptiometry ; dXA ; calf muscle ; magnetic resonance spectroscopy
dopamine ; nesiritide ; diuretic therapy ; renal function ; acute heart failure ; renal dysfunction
cRT ; New York Heart association class III ; IV heart failure ; left ventricular ejection ; QRs ; echocardiographic ; left ventricular dyssynchrony
left ventricular ;LV ; ejection fraction ; HF ; right-sided cardiac catheterization ; transthoracic echocardiography ; transmitral flow velocities ; mitral annulus velocities ; systole ; diastole
acute coronary syndromes ; CAD ; bNP ; NT-probNP levels ; CAD
HF ; lyso-paf-AT ; PAf-cpt ; PAf levels ; PAf-AH ; lp-PLA2
redo sternotomy ; aortic valve procedures ; bioprosthetic valve replacement ; dacron patch closure ; aortic valve repairs ; transcatheter aortic valve procedure ; open surgery ; aortic valve replacement
cutoff value ; plasma N-terminal pro-b-type natriuretic peptide ;NT-probNP ; acute heart failure ;HF ; emergency department ;ED
cardiac troponin T ; ctnt ; high-sensitivity assay ; n-terminal pro-b-type natriuretic peptide ;NT-probNP ; biomarkers ; incident HF ; HF risk prediction ; Atherosclerosis Risk in Communities ;ARIc
body mass index ;HR per kg/m ; fat mass ; fat-free mass index
men ;interquartile range ; median body mass index ;interquartile range ; COPd ; CHF ; cRF
reverse remodeling ; ejection fraction ; mortality ; HF hospitalizations ; dialysis patients
EH ; LV contractility ; CH ; LVEF ; confidence interval ; systolic blood pressure ; end-systolic volume
echocardiography ; dilated LV ; end-diastolic volume index ; mL/m2 ; LV ejection fraction ; mild MR ; mitral valve opening ; MS ; mVA ; pressure gradient
renal Optimization strategies Evaluation ;ROSe ; acute heart failure ; renal dysfunction ; glomerular filtration rate
BETs ; chromatin-mediated signal transduction ; Pol II ; co-activating transcription factor networks ; HF pathogenesis ; nuclear factor of activated T cells ; nFAT ; nuclear factor-Îºb ;NF-Îºb ; transcription factor
mortality ; hospitalization ; exercise tolerance ; quality of life ; cardiovascular events ; myocardial infarction ; congestive heart failure exacerbation ; arrhythmia ; cardiac death ; hypertension ; venous thrombolic events ; ischemic cerebrovascular events
all-cause ; cardiovascular mortality
interaction effect ; EO-cFUs ; diabetes ; patients without diabetes ; 10-EO-cFU ; EO-cFU ; VO2
immunoblotting ; radioenzymatic- ; fluorescence resonance ; energy transfer-based assays ; video edge detection ; epifluorescence microscopy ; l-type ca2(+) ; myocardial tissues ; isolated cardiomyocytes ; experimental HF
east ; Atrial fibrillation ; Stroke prevention trial ; AF at risk ; stroke ;CHA2DS2VASc score ; guideline-mandated usual care ; early rhythm control therapy
Exercise capacity ; peak oxygen consumption ;VO2 ; mL/kg/min ; QOL ; Minnesota Living with Heart Failure ;MLHF ; heart failure-related QOL
TAC-induced proteomic alterations ; mitochondrial-targeted peptide SS31 ; perturbed mitochondrial function ; TAC ; mitochondrial-targeted peptide drugs ; heart failure
low left ventricular ejection fraction ; patients ; HF ; preserved left ventricular ejection fraction ; hospital ; physicians ; acute ; outpatient settings
HF patients ;HFrEF ; preserved left ventricular ;LV ; ejection fraction ;HFpEF ; echo-Doppler studies ; n-terminal pro-brain-type natriuretic peptide assessment
low-volume EDs ; comorbidities ; hospitalized ; medium ; adjusted odds ratio ; aOR
cardiac transplant ; ECCT patients ; diabetes mellitus ; chronic kidney disease ; glomerular filtration rate
hABC Battery scores ; Health ABC HF Risk model ; discrimination ; c-index ;net-reclassification-improvement ; HF
cfi ; RMsea ; Self-Care Maintenance Scale ; cfi ; RMsea ; Self-Care management Scale ; cfi ; RMsea ; Self-Care Confidence scale
BAT ; quality-of-life score ; NYHA functional class ranking
hypoalbuminemia ; postoperative normalization ; albumin levels ; hypoalbuminemia ; decreasing albumin levels ; lVAD
rehospitalization ; acute myocardial infarction ;AMI ; kidney infection ; urinary tract infection ;UTI
patients with heart failure ;HF ; ischemic ; nonischemic cardiomyopathies ; pharmacological armamentarium ; implantable cardioverter defibrillators ; cardiac resynchronization therapy ; cardiac transplantation ; left ; ventricular assist devices
SAF ; PF ; PF ; centrale venous pressure ; hg ; sVR index ; dyn s/cm(5) ; cardiac index
women ; admission median ; bNP levels ; reduced EF ; preserved EF ; median bNP ; women ; men ; EF
heart failure admission ; heart transplantation ;LV assist device ; death ;hazard ratio
ejection fraction ; velocity ; circumferential shortening ; systolic elastance ; contractile efficiency ; acf ; allopurinol rats ; o2 consumption rate ; isolated cardiomyocytes ; extracellular flux analyzer
HFpEF ; LV structure ; normal geometry ; LV hypertrophy ;LVh ; relative wall thickness ;RWt ; CR ; LVh ; rwt
angiotensin receptor ; neprilysin inhibitor ; neprilysin inhibitor ; neprilysin inhibitor prodrug ; angiotensin receptor antagonist valsartan ; hypertension ; heart failure ; preserved ejection fraction
blood pressure ; mitral valve plasty ; degenerative MR ; p3 prolapse ; chordal ruptures ; triangular resection ; edge-to-edge anastomosis ; ring annuloplasty ; Physio Ring ;Edwards Lifesciences ; Irvine
shuttle walk test ; oxygen uptake ; muscular strength ; echocardiographic measures ; natriuretic peptide ; inflammatory markers ; depression ; beck depression inventory ; health-related quality of life ;Minnesota Living with Heart Failure Questionnaire ; Medical
interaction term analysis ; severely reduced LVEF ; long-term mortality ; preserved ; severely reduced LVEF
wstar-kyoto ; lean ZSF ; obese ZSF1 ; obese ZSF ; zSF1 ; high-fat diet ; metabolic ; renal ; echocardiographic evaluations ; hemodynamically
kaplan-meier curves ; log-rank testing ; risk stratification ; patients ; UM/VA/VA-RT cohorts
multivariate cox regression analyses ; AF type ; lack of hypertension ; sinus rhythm ;hazard ratio ;HR ; confidence interval ; ci
chronic HF-ref ; NYHA functional class II ; eGFR ; potassium ; eplerenone ; hyperkalemia ; wRF
fFM ; FM ; body fat distribution ; dual energy X-ray absorptiometry ; dXA ; non-diabetic patients ; chronic heart failure ;CHf ;cc ; non-cachectic CHF ; myocardial infarction-both
spironolactone ; end point of death ; hospitalization ; HF ;hazard ratio ; AAs
pulmonary arterial hypertension ; inoperable chronic thromboembolic pulmonary hypertension ; impaired right ventricular pump function ; pulmonary arterial hypertension medication ; stress echocardiography ; cardiopulmonary exercise testing
cardiovascular death ; HF hospitalization ; btes ; cardiovascular death ; HF hospitalization ; exercise group ;hazard ratio
severe CAD ; diabetes ; electrocardiographic Q waves ; left bundle branch block ; nondiabetes risk factors ; dyslipidemia ; hypertension ; tobacco
index ED visit ; low-volume ED cases ; death/all-cause readmission ; medium ; aOR ; high-volume EDs
implantable cardioverter-defibrillator deactivation ; implantable cardioverter-defibrillator deactivation
Cardiac magnetic resonance ; left atrial area ;hazard ratio ; 95% confidence interval ; pulmonary vascular resistance ;hazard ratio
HF units ; systolic ; left ventricular ejection fraction ; HF ; New York Heart Association class I to III ; echocardiographic ; cardiopulmonary exercise
end stage heart failure ; ABCd classification ; American college of Cardiology ; acc ;American Heart association ;AHA ; New York Heart association ;NYHA ; structural heart disease ; heart failure
mva ; continuity equation ;LV end-diastolic volume ; LV end-systolic volume ; mitral filling flow volume ; mVA ; velocity time integral ; mitral filling flow ; continuous wave ; doppler echocardiography ; MR ; mitral valve plasty
statitistical significance ; RM ; all-cause mortality ; sts HH ; credible interval ; crI ; TM
HFPSI ; Ann arbor Veterans' Affairs HF clinic ; va cohort ; HFPSI ; va-RT cohort ; va patients ; HFPSI
hFrEF ; diuretics ; co-morbidities ; wha class III
HF ; postoperative echocardiography ; LV ; end-diastolic volume index ; LV ; ejection fraction ; MR ; preserved mitral valve opening ; mitral valve area ; mVA ; mean pressure gradient
AAs ; spironolactone dose ; hyperkalemia ;potassium
preserved LVEF ; long-term mortality ; LVEF ;hazard ratio ;HR ; preserved LVEF
HFpEF ; male gender ;odds ratio ; nyha class III ; wt ; adherence ; medications
pulmonary arterial systolic pressure ;PASp ; right ventricular ; tricuspid annular plane systolic excursion ;TAPSe ; diastole ; end-systole ; heart failure ;HF ; cardiac risk
reverse remodeling ; pre-cRT LV ; end-diastolic dimension index ; global longitudinal strain ; left ventricle ; left atrial area ; right ventricular end-diastolic area index ; right atrial area ; right ventricular
receiver operating characteristic curve ;AUc ; e/e ; ratios ; pcWP ; confidence interval ;CI ; e/e ;septal ; ec/elateral ; e/emean
iRS1 ; iRS2 in the heart ; hyperinsulinemia ; myocardial insulin resistance ; cellular dysfunction ; iRS2 ; iRS2 ; iRS1 ; iRS2 double-knockout ; l-dko
natriuretic peptide ; n-terminal pro-b-type natriuretic peptide ; stable coronary artery disease ; natriuretic peptide ; bNP ; n-terminal fragment ;nt-probNP ; ventricular cardiomyocytes ; ventricular wall stress ; myocardial ischemia
trastuzumab-treated patients ; coronary artery disease ;HR ; hypertension ;HR ; weekly trastuzumab ; CHF
LVEF ; clinical composite response ; cRT ON ; cRT OFF ; LV end systolic volume index ; LV mass
tGF-Î² signaling ; inhibiting TGF-Î² receptor type I ; smad ; small-molecule inhibitors ; c-Kit+ cell yield ; epithelial ; mesenchymal transition markers ; pluripotency marker nanog ; c-Kit+ cell differentiation ; cardiomyocyte-like cells
systolic heart failure ;ejection fraction ; ivabradine ; SHIft ; systolic Heart Failure Treatment ; If inhibitor ivabradine trial ; ivabradine ; ivabradine ; echocardiographic substudy
liberal transfusion protocols ; short-term mortality rates ; aggressive protocols ; relative risk ; trial ; acute coronary syndrome
risk ; unplanned readmission ; familiar physician ; adjusted hazard ratio ;HR ; confidence interval ;CI ; unfamiliar physician
Hazard ratios ; tAPse ; pasp ;hazard ratio ; tAPse ; pb ; New York Heart Association functional class
hek ;human embryonic kidney ; cells overexpressing ; Î²1AR ; s1PR1 ; Î²1AR downregulation ; sphingosine-1-phosphate ; s1PR1 agonist ; isoproterenol ; Î²-adrenergic receptor agonist
kansas City Cardiomyopathy Questionnaire ; Minnesota Living with Heart Failure Questionnaire ; depressive symptoms ; beck depression inventory ; zung self-rated depression scores ; natriuretic peptide ; endothelial function ;flow-mediated dilatation ; left ventricular diastolic function
Renal function ; Chronic Kidney Disease Epidemiology Collaboration equation ; glomerular filtration rate ; egFR
paraDIGm-HF ; stabilized chronic heart failure ; systolic dysfunction ;LV EF ; functional class NYHA II-III ; bNP ; bNP ; cardiovascular death ; hospitalization for heart failure ; arni ; sacubiltril ; valsartan
hyperkalemia ; African Americans ; non-AAs ; white ; New York Heart Association ;NYha ; class III ; IV HF ; left ventricular dysfunction ; spironolactone ; aldactone Evaluation Study ;RALes
Odds ratios ; cardiovascular events ; atrial fibrillation ; left ventricular ejection fraction ; diabetes mellitus ; peripheral vascular disease ; myocardial infarction ; heart failure ; stroke
diastolic function ; ecb ; ventricular-arterial coupling
disease risk score ; dRS-stratified analyses ; saxagliptin ; sitagliptin ; ci ; saxagliptin ; pioglitazone ; saxagliptin ; sulfonylureas ; saxagliptin ; insulin
i ; revascularization ;coronary artery bypass surgery ; hazard ratio ;HR ; percutaneous coronary intervention ; HR ; systolic blood pressure ; left bundle branch block pattern ; baseline electrocardiogram ; IE
biomedical treatment ; biomedical treatment ; CHm ; left ventricular ejection fraction ; left ventricular diastolic end diameter
open-label crossover study ; stable heart failure patients ; left ventricular ejection fraction ; arg16/ gln27 ; gly16/ glu27 haplotype ; Î²2-receptor ; carvedilol ; metoprolol
angiotensin-converting enzyme inhibitors ;angiotensin receptor blockers ; interquartile range ; Î²-blockers
ivabradine ; diastolic mitral flow velocity ; early diastolic mitral mitral annular velocity ; exercise capacity ; ivabradine ; oxygen uptake
PAF ; biosynthetic enzymes ;lyso-paf acetyltransferase ;lyso-paf-at ; dithiothreitol ; dt ; cdp ; choline ; 1-alkyl-2-acetyl-sn-glycerol ; cholinephosphotransferase ; pf-cpt ; catabolic isoenzymes ; paf-acetylhydrolase ; pf-AH ; lipoprotein-associated phospholipase A2 ; lp-PLA2]
low-volume ED cases ; death ;hospitalization ;ED visit ; aOR ; high-volume ED cases ; aOR
ivabradine group ; follow-up exercise capacity ; peak oxygen uptake ; early diastolic mitral flow velocity ; early diastolic mitral
Health Buddy Program ; risk-adjusted all-cause mortality ;hazard ratio ;HR ; confidence interval ;CI ; inpatient admissions
multivariable-adjusted hazard ratios ;
ctnt ; NT-probNP ;laboratory report ; aRIC HF model ; systolic blood pressure ; antihypertensive medication use ; smoking ; diabetes ; body mass index ; coronary heart disease ; heart rate ; receiver operating characteristic curve ;AUC ; discrimination improvement ; net reclassification improvement ; nRI
eplerenone ; hyperkalemia ; worsening renal function ; wRF ; EMPHASIS-HF ; heart failure ; reduced ejection fraction ;HF-ref ; New York Heart association ;NYHA ; glomerular filtration rate ; e gFR ; serum potassium
NYha classification ; class III ; class III ; class I ; patient ; quality of life ; Duke Activity Status index ; Kansas City Cardiomyopathy Questionnaire ; walk test distance ;SD
low-dose dopamine ; cumulative urine volume ;dopamine
low-dose nesiritide ; cumulative urine volume ;nesiritide ; mL ; placebo ; cystatin c level ;nesiritide
Nordic walking ; functional capacity ; kwt ; self-reported physical activity ; right grip strength ; depressive symptoms ;Hospital anxiety and depression Scale score
hyperkalemia ; wRF ; diabetes ; eGFR ; systolic blood pressure ; hg ;potassium ; hyperkalemia ; wr ; cardiovascular mortality
haard ratio ;HR ; confidence interval ; ci ; baseline glomerular filtration rate ;HR ; chronic obstructive pulmonary disease ; diabetes ;HR ; peripheral vascular disease ; left ventricular ejection fraction ; h ; inappropriate iCD shocks ; New York Heart association ; atrial fibrillation ; congestive HF
peak oxygen uptake ; hazard ratio ; h ; confidence interval ; ci ; ventilatory efficiency slope ; HR ; hemoglobin ; left ventricular ejection fraction ; HR=00.948 ; renal function ; renal disease ; sodium
Kansas City Cardiomyopathy Questionnaire summary ; Minnesota Living with Heart Failure Questionnaire ; Beck depression inventory ; zung ; flow-mediated dilatation diameter ; fes group ; natriuretic peptide
CHF ; ods Ratio ; ods Ratio ; hCT chest radiation ; hypertension ; r13058338 ; genes coding ; NAD(ph-oxidase subunit RAC2 ; hbf ; doxorubicin efflux transporter ABCc
